Biomedical Data Sciences, GlaxoSmithKline. Results of investigation of ‘all adverse events and verbatim terms that might possibly refer to an event that could be part of suicidal thinking and/or suicide attempt’ henceforth referred to as ‘possibly suicide-related’ from review of Pediatric Studies. May 15, 2003. [Redacted] [unpublished]
Abramowitz JS, Moore EL, Braddock AE, Harrington DL. Self-help cognitive-behavioral therapy with minimal therapist contact for social phobia: a controlled trial.
Journal of Behavior Therapy and Experimental Psychiatry. 2009;40:98–105. [
PubMed: 18514614]
Acarturk C, de Graaf R, van Straten A, Have MT, Cuijpers P. Social phobia and number of social fears, and their association with comorbidity, health-related quality of life and help seeking: a population-based study.
Social Psychiatry and Psychiatric Epidemiology. 2008;43:273–9. [
PubMed: 18219433]
Acarturk C, Smit F, de Graaf R, van Straten A, Ten Have M, Cuijpers P. Economic costs of social phobia: a population-based study.
Journal of Affective Disorders. 2009;115:421–9. [
PubMed: 19012968]
Adler LA, Liebowitz M, Kronenberger W, Qiao M, Rubin R, Hollandbeck M, et al. Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder.
Depression and Anxiety. 2009;26:212–21. [
PubMed: 19194995]
AGREE Collaboration. Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project.
Quality and Safety in Health Care. 2003;12:18–23. [
PMC free article: PMC1743672] [
PubMed: 12571340]
Albano AM, Mallick R, Tourian K, Zhang HF, Kearney C. Children and adolescents with social anxiety disorder: school refusal and improvement with venlafaxine ER relative to placebo. European Neuropsychopharmacology. 2004;14:S307–S08.
Alden LE. Short-term structured treatment for avoidant personality disorder.
Journal of Consulting and Clinical Psychology. 1989;57:756–64. [
PubMed: 2600246]
Alden LE, Taylor CT. Relational treatment strategies increase social approach behaviors in patients with Generalized Social Anxiety Disorder.
Journal of Anxiety Disorders. 2011;25:309–18. [
PubMed: 21094019]
Allgulander C, editor. Efficacy of paroxetine in social phobia – a single-center double-blind study of 96 symptomatic volunteers randomized to treatment with paroxetine 20–50mg or placebo for 3 months; 11th European College of Neuropsychopharmacology Congress; 1998 31 October – 4 November; Paris, France.
Allgulander C. Paroxetine in social anxiety disorder: a randomized placebo-controlled study.
Acta Psychiatrica Scandinavica. 1999;100:193–98. [
PubMed: 10493085]
Allgulander CN. A prospective study of 86 new patients with social anxiety disorder.
Acta Psychiatrica Scandinavica. 2001;103:447–52. [
PubMed: 11401659]
Allgulander C, Mangano R, Zhang J, Dahl A, Lepola U, Sjodin I, et al. Efficacy of venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine.
Human Psychopharmacology. 2004;19:387–96. [
PubMed: 15303242]
Allgulander C, Jorgensen T, Wade A, Francois C, Despiegel N, Auquier P, et al. Health-related quality of life (HRQOL) among patients with generalised anxiety Disorder: evaluation conducted alongside an escitalopram relapse prevention trial.
Current Medical Research and Opinion. 2007;23:2543–9. [
PubMed: 17825130]
Almlöv J, Carlbring P, Källqvist K, Paxling B, Cuijpers P, Andersson G. Therapist effects in guided internet-delivered CBT for anxiety disorders.
Behavioural and Cognitive Psychotherapy. 2011;39:311–22. [
PubMed: 21144121]
Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, Bryson H, et al. Disability and quality of life impact of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project.
Acta Psychiatrica Scandinavica Supplementum. 2004:38–46. [
PubMed: 15128386]
American Autoimmune Related Diseases Association.
The Cost Burden of Autoimmune Disease: The Latest Front in the War on Healthcare Spending. Eastpoint, MI: American Autoimmune Related Diseases Association; 2011. Available from:
www.aarda.org/pdf/cbad.pdf.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders – Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Association; 2000.
Amir N, Beard C, Taylor C, Klumpp H, Elias J, Burns M, et al. Attention training in individuals with generalized social phobia: a randomized controlled trial.
Journal of Consulting and Clinical Psychology. 2009;77:961–73. [
PMC free article: PMC2796508] [
PubMed: 19803575]
Amir N, Taylor C. Interpretation training in individuals with generalized social anxiety disorder: a randomized controlled trial.
Journal of Consulting and Clinical Psychology. 2012;80:497–511. [
PMC free article: PMC3365642] [
PubMed: 22250851]
Andersson G, Carlbring P. Commentary on Berger, Hohl, and Caspar's (2009) internet-based treatment for social phobia: a randomized controlled trial.
Journal of Clinical Psychology. 2009;65:1036–38. [
PubMed: 19688814]
Andersson G, Carlbring P, Furmark T. Therapist experience and knowledge acquisition in internet-delivered CBT for social anxiety disorder: a randomized controlled trial.
PLoS ONE. 2012;7:e37411. [
PMC free article: PMC3359350] [
PubMed: 22649526]
Andersson G, Carlbring P, Holmström A, Sparthan E, Furmark T, Nilsson-Ihrfelt E, et al. Internet-based self-help with therapist feedback and in vivo group exposure for social phobia: a randomized controlled trial.
Journal of Consulting and Clinical Psychology. 2006;74:677–86. [
PubMed: 16881775]
Andersson G, Waara J, Jonsson U, Malmaeus F, Carlbring P, Ost L. Internet-based self-help versus one-session exposure in the treatment of spider phobia: a randomized controlled trial.
Cognitive Behaviour Therapy. 2009;38:114–20. [
PubMed: 20183690]
Andrews G, Davies M, Titov N. Effectiveness randomized controlled trial of face to face versus internet cognitive behaviour therapy for social phobia.
Australian and New Zealand Journal of Psychiatry. 2011;45:337–40. [
PubMed: 21323490]
Asakura S, Tajima O, Koyama T. Fluvoxamine treatment of generalized social anxiety disorder in Japan: a randomized double-blind, placebo-controlled study.
International Journal of Neuropsychopharmacology. 2007;10:263–74. [
PubMed: 16573847]
Atmaca M, Kuloglu M, Tezcan E, Unal A. Efficacy of citalopram and moclobemide in patients with social phobia: some preliminary findings.
Human Psychopharmacology. 2002;17:401–05. [
PubMed: 12457375]
Aune T, Stiles TC, Svarva K, Aune T, Stiles TC, Svarva K. Psychometric properties of the Social Phobia and Anxiety Inventory for Children using a non-American population-based sample.
Journal of Anxiety Disorders. 2008;22:1075–86. [
PubMed: 18182274]
Baer S, Garland E. Pilot study of community-based cognitive behavioral group therapy for adolescents with social phobia.
Journal of the American Academy of Child and Adolescent Psychiatry. 2005;44:258–64. [
PubMed: 15725970]
Baker SL, Heinrichs N, Kim HJ, Hofmann SG. The Liebowitz Social Anxiety Scale as a self-report instrument: a preliminary psychometric analysis.
Behaviour Research and Therapy. 2002;40:701–15. [
PubMed: 12051488]
Baldwin DS, Bobes J, Stein DJ, Scharwächter I, Faure M. Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine Study Group.
The British Journal of Psychiatry. 1999;175:120–26. [
PubMed: 10627793]
Baldwin DS, Cooper JA, Huusom AK, Hindmarch I. A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder.
International Clinical Psychopharmacology. 2006;21:159–69. [
PubMed: 16528138]
Baldwin JS, Dadds MR. Reliability and validity of parent and child versions of the Multidimensional Anxiety Scale for children in community samples.
Journal of the American Academy of Child and Adolescent Psychiatry. 2007;46:252–60. [
PubMed: 17242629]
Barbui C, Esposito E, Cipriani A. Selective serotonin reuptake inhibitors and risk of suicide: a systematic review of observational studies.
Canadian Medical Association Journal. 2009;180:291–7. [
PMC free article: PMC2630355] [
PubMed: 19188627]
Barnett S, Kramer M, Casat C, Connor K, Davidson J. Efficacy of olanzapine in social anxiety disorder: a pilot study.
Journal of Psychopharmacology. 2002;16:365–68. [
PubMed: 12503837]
Beasley CM Jr., Koke SC, Nilsson ME, Gonzales JS. Adverse events and treatment discontinuations in clinical trials of fluoxetine in major depressive disorder: an updated meta-analysis.
Clinical Therapeutics. 2000;22:1319–30. [
PubMed: 11117656]
Becker ES, Rinck M, Turke V, Kause P, Goodwin R, Neumer S, et al. Epidemiology of specific phobia subtypes: findings from the Dresden Mental Health Study.
European Psychiatry. 2007;22:69–74. [
PubMed: 17157482]
Beesdo K, Knappe S, Pine DS. Anxiety and anxiety disorders in children and adolescents: developmental issues and implications for DSM-V.
The Psychiatric Clinics of North America. 2009;32:483–524. [
PMC free article: PMC3018839] [
PubMed: 19716988]
Beidel DC, Turner SM, Morris TL. Psychopathology of childhood social phobia.
Journal of the American Academy of Child and Adolescent Psychiatry. 1999;38:643–50. [
PubMed: 10361781]
Beidel DC, Turner SM, Morris TL. Behavioral treatment of childhood social phobia.
Journal of Consulting and Clinical Psychology. 2000;68:1072–80. [
PubMed: 11142541]
Beidel DC, Turner SM, Sallee FR, Ammerman RT, Crosby LA, Pathak S. SET-C versus fluoxetine in the treatment of childhood social phobia.
Journal of the American Academy of Child and Adolescent Psychiatry. 2007;46:1622–32. [
PubMed: 18030084]
Berger T, Hohl E, Caspar F. Internet-based treatment for social phobia: a randomized controlled trial.
Journal of Clinical Psychology. 2009;65:1021–35. [
PubMed: 19437505]
Berger T, Hohl E, Caspar F. [Internet-based treatment for social phobia: a 6-month follow-up]. Zeitschrift fur Klinische Psychologie und Psychotherapie: Forschung und Praxis. 2010;39:217–21.
Berlin JA. Does blinding of readers affect the results of meta-analyses? University of Pennsylvania Meta-analysis Blinding Study Group.
Lancet. 1997;350:185–6. [
PubMed: 9250191]
Birmaher BB. Psychometric properties of the screen for child anxiety related emotional disorders (SCARED): a replication study.
Journal of the American Academy of Child and Adolescent Psychiatry. 1999;38:1230–36. [
PubMed: 10517055]
Bjornsson AS, Bidwell LC, Brosse AL, Carey G, Hauser M, Mackiewicz Seghete KL, et al. Cognitive-behavioral group therapy versus group psychotherapy for social anxiety disorder among college students: a randomized controlled trial.
Depression and Anxiety. 2011;28:1034–42. [
PubMed: 22076970]
Black B, Uhde T. Treatment of elective mutism with fluoxetine: a double-blind, placebo-controlled study.
Journal of the American Academy of Child and Adolescent Psychiatry. 1994;33:1000–06. [
PubMed: 7961338]
Blanco C, Heimberg RG, Schneier FR, Fresco DM, Chen HN, Turk CL, et al. A placebo-controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder.
Archives of General Psychiatry. 2010;67:286–95. [
PMC free article: PMC2856667] [
PubMed: 20194829]
Blanco C, Bragdon LB, Schneier FR, Liebowitz MR. The evidence-based pharmacotherapy of social anxiety disorder.
International Journal of Neuropsychopharmacology. 2012;6:427–42. [
PubMed: 14609440]
Blomhoff S, Haug TT, Hellstrom K, Holme I, Humble M, Madsbu HP, et al. Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia.
British Journal of Psychiatry. 2001;179:23–30. [
PubMed: 11435264]
Boettcher J, Berger T, Renneberg B. Internet-based attention training for social anxiety: a randomized controlled trial. Cognitive Therapy and Research. 2011;36:522–36.
Bögels SM. Task concentration training versus applied relaxation, in combination with cognitive therapy, for social phobia patients with fear of blushing, trembling, and sweating.
Behaviour Research and Therapy. 2006;44:1199–210. [
PubMed: 16225841]
Bögels SM, Voncken MJ. Social skills training versus cognitive therapy for social anxiety disorder characterized by fear of blushing, trembling, or sweating. International Journal of Cognitive Therapy. 2008;1:138–50.
Bogetto F, Bellino S, Revello RB, Patria L. Discontinuation syndrome in dysthymic patients treated with selective serotonin reuptake inhibitors: a clinical investigation.
CNS Drugs. 2002;16:273–83. [
PubMed: 11945110]
Boley TM, Belangee KN, Markwell S, Hazelrigg SR. The effect of thoracoscopic sympathectomy on quality of life and symptom management of hyperhidrosis.
Journal of the American College of Surgeons. 2007;204:435–8. [
PubMed: 17324778]
Book SW, Thomas SE, Randall PK, Randall CL. Paroxetine reduces social anxiety in individuals with a co-occurring alcohol use disorder.
Journal of Anxiety Disorders. 2008;22:310–18. [
PMC free article: PMC2254554] [
PubMed: 17448631]
Borge FM, Hoffart A, Sexton H, Clark D, Markowitz J, McManus F. Residential cognitive therapy versus residential interpersonal therapy for social phobia: a randomized clinical trial.
Journal of Anxiety Disorders. 2008;22:991–1010. [
PubMed: 18035519]
Borge FM, Hoffart A, Sexton H, Martinsen E, Gude T, Hedley LM, et al. Pre-treatment predictors and in-treatment factors associated with change in avoidant and dependent personality disorder traits among patients with social phobia.
Clinical Psychology and Psychotherapy. 2010;17:87–99. [
PubMed: 19630068]
Borgeat F, Stankovic M, Khazaal Y, Rouget B, Baumann M, Riquier F, et al. Does the form or the amount of exposure make a difference in the cognitive-behavioral therapy treatment of social phobia?
The Journal of Nervous and Mental Disease. 2009;197:507–13. [
PubMed: 19597358]
Botella C, Gallego MJ, Garcia PA, Guillen V, Baños RM, Quero S, et al. An internet-based self-help treatment for fear of public speaking: a controlled trial.
Cyberpsychology, Behavior and Social Networking. 2010;13:407–21. [
PubMed: 20712499]
Brambilla P, Cipriani A, Hotopf M, Barbui C. Side-effect profile of fluoxetine in comparison with other SSRIs, tricyclic and newer antidepressants: a meta-analysis of clinical trial data.
Pharmacopsychiatry. 2005;38:69–77. [
PubMed: 15744630]
Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36.
Journal of Health Economics. 2002;21:271–92. [
PubMed: 11939242]
Briggs A, Sculpher M, Claxton K. Decision Modelling for Health Economic Evaluation. Oxford: Oxford University Press; 2006.
Brooks R. Quality of life measures.
Critical Care Medicine. 1996;24:1769. [
PubMed: 8874318]
Bruce SE, Yonkers KA, Otto MW, Eisen JL, Weisberg RB, Pagano M, et al. Influence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder, social phobia, and panic disorder: a 12-year prospective study.
The American Journal of Psychiatry. 2005;162:1179–87. [
PMC free article: PMC3272761] [
PubMed: 15930067]
Bunevicius A, Peceliuniene J, Mickuviene N, Valius L, Bunevicius R, Bunevicius A, et al. Screening for depression and anxiety disorders in primary care patients.
Depression and Anxiety. 2007;24:455–60. [
PubMed: 17117433]
Burlingame GM, Lambert MJ, Reisinger CW, Neff WM, Mosier J. Pragmatics of tracking mental health outcomes in a managed care setting.
The Journal of Behavioral Health Services and Research. 1995;22:226–36. [
PubMed: 10144458]
Burrows GE. Moclobemide in social phobia. A double-blind, placebo-controlled clinical study.
European Archives of Psychiatry and Clinical Neuroscience. 1997;247:71–80. [
PubMed: 9177952]
Cabrera J, Emir B, Dills D, Murphy K, Whalen E, Clair A. Characterizing and understanding body weight patterns in patients treated with pregabalin.
Current Medical Research and Opinion. 2012;28:1027–37. [
PubMed: 22494020]
Carlbring P, Gunnarsdóttir M, Hedensjö L, Andersson G, Ekselius L, Furmark T. Treatment of social phobia: randomised trial of internet-delivered cognitive-behavioural therapy with telephone support.
British Journal of Psychiatry. 2007;190:123–28. [
PubMed: 17267928]
Carlbring P, Nordgren LB, Furmark T, Andersson G. Long-term outcome of internet-delivered cognitive-behavioural therapy for social phobia: a 30-month followup.
Behaviour Research and Therapy. 2009;47:848–50. [
PubMed: 19631312]
Carlbring P, Apelstrand M, Sehlin H, Amir N, Rousseau A, Hofmann SG, et al. Internet-delivered attention bias modification training in individuals with social anxiety disorder – a double blind randomized controlled trial.
BMC Psychiatry. 2012;12:66. [
PMC free article: PMC3464865] [
PubMed: 22731889]
Cartwright-Hatton S, McNally D, Field AP, Rust S, Laskey B, Dixon C, et al. A new parenting-based group intervention for young anxious children: results of a randomized controlled trial.
Journal of the American Academy of Child and Adolescent Psychiatry. 2011;50:242–51. [
PubMed: 21334564]
Chartier MJ, Walker JR, Stein MB. Considering comorbidity in social phobia.
Social psychiatry and psychiatric epidemiology. 2003;38:728–34. [
PubMed: 14689178]
Chavira DA, Stein MB, Bailey K, Stein MT. Comorbidity of generalized social anxiety disorder and depression in a pediatric primary care sample.
Journal of Affective Disorders. 2004;80:163–71. [
PubMed: 15207929]
Chinn S. A simple method for converting an odds ratio to effect size for use in meta-analysis.
Statistics in Medicine. 2000;19:3127–31. [
PubMed: 11113947]
Chung YS, Kwon JH. The efficacy of bibliotherapy for social phobia. Brief Treatment and Crisis Intervention. 2008;8
Clark DM. A controlled trial of cognitive therapy and pharmacotherapy in the treatment of social phobia. National Research Register. 1998
Clark DM. Implementing NICE guidelines for the psychological treatment of depression and anxiety disorders: the IAPT experience.
International review of psychiatry. 2011;23:318–27. [
PMC free article: PMC3212920] [
PubMed: 22026487]
Clark DM, Wells A. A cognitive model of social phobia. In: Heimberg RG, Liebowitz M, Hope DA, Schneier FR, editors. Social Phobia: Diagnosis, Assessment and Treatment. New York: Guildford Press; 1995. pp. 69–93.
Clark DM, Salkovskis PM, Hackmann A, Middleton H, Anastasiades P, Gelder M. A comparison of cognitive therapy, applied relaxation and imipramine in the treatment of panic disorder.
The British Journal of Psychiatry. 1994;164:759–69. [
PubMed: 7952982]
Clark DM, Ehlers A, McManus F, Hackmann A, Fennell M, Campbell H, et al. Cognitive therapy versus fluoxetine in generalized social phobia: A randomized placebo-controlled trial.
Journal of Consulting and Clinical Psychology. 2003;71:1058–67. [
PubMed: 14622081]
Clark DM, Ehlers A, Hackmann A, McManus F, Fennell M, Grey N, et al. Cognitive therapy versus exposure and applied relaxation in social phobia: A randomized controlled trial.
Journal of Consulting and Clinical Psychology. 2006;74:568–78. [
PubMed: 16822113]
Clark DM, Layard R, Smithies R, Richards DA, Suckling R, Wright B. Improving access to psychological therapy: Initial evaluation of two UK demonstration sites.
Behaviour Research and Therapy. 2009;47:910–20. [
PMC free article: PMC3111658] [
PubMed: 19647230]
Clark DM, Wild J, Grey N, Stott R, Liness S, Deale A, et al. Self-Study Enhances the Effects of Cognitive Therapy for Social Anxiety Disorder: A Randomized Controlled Trial. 2012.
Cochrane Collaboration. Review Manager (RevMan) Version 5.1 [Computer programme]. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration; 2011.
Coles ME, Gibb BE, Heimberg RG. Psychometric evaluation of the Beck Depression Inventory in adults with social anxiety disorder.
Depression and Anxiety. 2001;14:145–8. [
PubMed: 11668668]
Connor KMC. Botulinum toxin treatment of social anxiety disorder with hyperhidrosis: a placebo-controlled double-blind trial.
Journal of Clinical Psychiatry. 2006;67:30–36. [
PubMed: 16426085]
Connor KM, Davidson JR, Churchill LE, Sherwood A, Foa E, Weisler RH. Psychometric properties of the Social Phobia Inventory (SPIN). New self-rating scale.
The British Journal of Psychiatry. 2000;176:379–86. [
PubMed: 10827888]
Connor KM, Kobak KA, Churchill LE, Katzelnick D, Davidson JR. Mini-SPIN: a brief screening assessment for generalized social anxiety disorder.
Depression and Anxiety. 2001;14:137–40. [
PubMed: 11668666]
Connor KM, Cook JL, Davidson JR. Botulinum toxin treatment of social anxiety disorder with hyperhidrosis: a double-blind placebo-controlled trial. Neuropsychopharmacology. 2004;29 Suppl 1:S96.
Connor KM, Davidson JR, Chung H, Yang R, Clary CM. Multidimensional effects of sertraline in social anxiety disorder.
Depression and Anxiety. 2006;23:6–10. [
PubMed: 16216019]
Costello EJ, Mustillo S, Erkanli A, Keeler G, Angold A. Prevalence and development of psychiatric disorders in childhood and adolescence.
Archives of General Psychiatry. 2003;60:837–44. [
PubMed: 12912767]
Cottraux J, Note I, Albuisson E, Yao SN, Note B, Mollard E, et al. Cognitive behavior therapy versus supportive therapy in social phobia: a randomized controlled trial.
Psychotherapy and Psychosomatics. 2000;69:137–46. [
PubMed: 10773778]
Craske MG, Rauch SL, Ursano R, Prenoveau J, Pine DS, Zinbarg RE. What is an anxiety disorder?
Depression and Anxiety. 2009;26:1066–85. [
PubMed: 19957279]
Craske MG, Stein MB, Sullivan G, Sherbourne C, Bystritsky A, Rose RD, et al. Disorder-specific impact of coordinated anxiety learning and management treatment for anxiety disorders in primary care.
Archives of General Psychiatry. 2011;68:378–88. [
PMC free article: PMC3074172] [
PubMed: 21464362]
Crosby J, Cooper PJ, Creswell C. Characteristics of social anxiety disorder in middle childhood. in preparation.
Curtis GC, Magee WJ, Eaton WW, Wittchen HU, Kessler RC. Specific fears and phobias. Epidemiology and classification.
The British Journal of Psychiatry. 1998;173:212–7. [
PubMed: 9926096]
Curtis L. Unit Costs of Health and Social Care 2010. Canterbury: Personal Social Services Research Unit, University of Kent; 2010.
Curtis L. Unit Costs of Health and Social Care 2012. Canterbury: Personal Social Services Research Unit, University of Kent; 2012.
Davidson J, Yaryura-Tobias J, DuPont R, Stallings L, Barbato L, van der Hoop R, et al. Fluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorder.
Journal of Clinical Psychopharmacology. 2004;24:118–25. [
PubMed: 15206657]
Davidson JR, Foa EB, Huppert JD, Keefe FJ, Franklin ME, Compton JS, et al. Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia.
Archives of General Psychiatry. 2004;61:1005–13. [
PubMed: 15466674]
Davidson JR, Hemby LW, Barbato L, van der Hoop RG. Fluvoxamine controlled release for the treatment of generalized social anxiety disorder; 39th Annual Meeting of the American College of Neuropsychopharmacology 2000; Dec 10 14; San Juan; Puerto Rico. 2000. p. 161.
Davidson JR, Hughes DL, George LK, Blazer DG. The epidemiology of social phobia: findings from the Duke Epidemiological Catchment Area Study.
Psychological Medicine. 1993;23:709–18. [
PubMed: 8234577]
Davidson JR, Miner CM, De Veaugh-Geiss J, Tupler LA, Colket JT, Potts NL. The Brief Social Phobia Scale: a psychometric evaluation.
Psychological Medicine. 1997;27:161–6. [
PubMed: 9122296]
Davidson JR, Potts N, Richichi E, Krishnan R, Ford S, Smith R, et al. Treatment of social phobia with clonazepam and placebo.
Journal of Clinical Psychopharmacology. 1993;13:423–28. [
PubMed: 8120156]
Davis TE, Jenkins WS, Rudy BM. Empirical status of one-session treatment. In: Davis TE, Ollendick TH, Öst LG, editors. Intensive One-Session Treatment of Specific Phobias. New York: Springer; 2012.
De Los Reyes A, Alfano CA, Beidel DC. The relations among measurements of informant discrepancies within a multisite trial of treatments for childhood social phobia.
Journal of Abnormal Child Psychology. 2010;38:395–404. [
PubMed: 20013046]
Delgado PL. Monoamine depletion studies: implications for antidepressant discontinuation syndrome.
Journal of Clinical Psychiatry. 2006;67(Suppl. 4):22–6. [
PubMed: 16683859]
den Boer JA, van Vliet IM, Westenberg HG. A double-blind placebo controlled study of fluvoxamine in social phobia. Clinical Neuropharmacology. 1992;15:615.
Department of Health. National Service Framework for Mental Health. London: Department of Health; 1999.
Depping AM, Komossa K, Kissling W, Leucht S. Second-generation antipsychotics for anxiety disorders.
Cochrane Database of Systematic Reviews. 2010;12 CD008120. [
PubMed: 21154392]
Dias S, Sutton AJ, Ades AE, Welton NJ. Evidence synthesis for decison making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials.
Medical Decision Making. 2012;33:607–17. [
PMC free article: PMC3704203] [
PubMed: 23104435]
Dineen-Wagner KDB. A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder.
Archives of General Psychiatry. 2004;61:1153–62. [
PubMed: 15520363]
Dolan P. Modeling valuations for EuroQol health states.
Medical Care. 1997;35:1095–108. [
PubMed: 9366889]
Dolan P, Gudex C, Kind P, Williams A. The time trade-off method: results from a general population study.
Health Economics. 1996;5:141–54. [
PubMed: 8733106]
Dugan SE, Fuller MA. Duloxetine: a dual reuptake inhibitor.
The Annals of Pharmacotherapy. 2004;38:2078–85. [
PubMed: 15522980]
Eccles M, Freemantle N, Mason J. North of England evidence based guidelines development project: methods of developing guidelines for efficient drug use in primary care.
BMJ. 1998;316:1232–35. [
PMC free article: PMC1112989] [
PubMed: 9553004]
Emmelkamp PM, Benner A, Kuipers A, Feiertag GA, Koster HC, van Apeldoorn FJ. Comparison of brief dynamic and cognitive-behavioural therapies in avoidant personality disorder.
British Journal of Psychiatry. 2006;189:60–64. [
PubMed: 16816307]
Erwin BA, Heimberg RG, Marx BP, Franklin ME. Traumatic and socially stressful life events among persons with social anxiety disorder.
Journal of Anxiety Disorders. 2006;20:896–914. [
PubMed: 16490343]
Fahlen T. Personality traits in social phobia, II: Changes during drug treatment.
Journal of Clinical Psychiatry. 1995;56:569–73. [
PubMed: 8530333]
Fava M, Mulroy R, Alpert J, Nierenberg AA, Rosenbaum JF. Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine.
The American Journal of Psychiatry. 1997;154:1760–2. [
PubMed: 9396960]
Fava M, Rush AJ, Alpert JE, Balasubramani GK, Wisniewski SR, Carmin CN, et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report.
The American Journal of Psychiatry. 2008;165:342–51. [
PubMed: 18172020]
Feehan M, McGee R, Raja SN, Williams SM. DSM-III-R disorders in New Zealand 18–year-olds.
The Australian and New Zealand Journal of Psychiatry. 1994;28:87–99. [
PubMed: 8067973]
Fehm L, Beesdo K, Jacobi F, Fiedler A. Social anxiety disorder above and below the diagnostic threshold: prevalence, comorbidity and impairment in the general population.
Social Psychiatry and Psychiatric Epidemiology. 2008;43:257–65. [
PubMed: 18084686]
Feltner DE, Davidson JR, Pollack MH, Stein MB, Futterer R, Jefferson JW, et al. A placebo-controlled, double-blind study of pregabalin treatment of social anxiety disorder: outcome and predictors of response; 39th Annual Meeting of the American College of Neuropsychopharmacology; San Juan, Puerto Rico. 10–14 Dec, 2000.
Feltner DE, Liu-Dumaw M, Schweizer E, Bielski R. Efficacy of pregabalin in generalized social anxiety disorder: results of a double-blind, placebo-controlled, fixed-dose study.
International Clinical Psychopharmacology. 2011;26:213–20. [
PubMed: 21368587]
Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves.
Health Economics. 2001;10:779–87. [
PubMed: 11747057]
Fergusson D, Doucette S, Glass KC, Shapiro S, Healy D, Hebert P, et al. Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials.
BMJ. 2005;330:396. [
PMC free article: PMC549110] [
PubMed: 15718539]
Fischer JE, Bachmann LM, Jaeschke R. A readers' guide to the interpretation of diagnostic test properties: clinical example of sepsis.
Intensive Care Medicine. 2003;29:1043–51. [
PubMed: 12734652]
Ford T, Goodman R, Meltzer H. The British Child and Adolescent Mental Health Survey 1999: the prevalence of DSM-IV disorders.
Journal of the American Academy of Child and Adolescent Psychiatry. 2003;42:1203–11. [
PubMed: 14560170]
Franchini AJ, Dias S, Ades AE, Jansen JP, Welton NJ. Accounting for correlation in network meta-analysis with multi-arm trials.
Research Synthesis Methods. 2012;3:142–60. [
PubMed: 26062087]
François C, Montgomery SA, Despiegel N, Aballéa S, Roïz J, Auquier P. Analysis of health-related quality of life and costs based on a randomised clinical trial of escitalopram for relapse prevention in patients with generalised social anxiety disorder.
International Journal of Clinical Practice. 2008;62:1693–702. [
PMC free article: PMC2704928] [
PubMed: 18759783]
François C, Despiegel N, Maman K, Saragoussi D, Auquier P. Anxiety disorders, major depressive disorder and the dynamic relationship between these conditions: treatment patterns and cost analysis.
Journal of Medical Economics. 2010;13:99–109. [
PubMed: 20078336]
Fraser J, Kirkby KC, Daniels B, Gilroy L, Montgomery IM. Three versus six sessions of computer-aided vicarious exposure treatment for spider phobia. Behaviour Change. 2001;18:213–23.
Fresco DM, Coles ME, Heimberg RG, Liebowitz MR, Hami S, Stein MB, et al. The Liebowitz Social Anxiety Scale: a comparison of the psychometric properties of self-report and clinician-administered formats.
Psychological Medicine. 2001;31:1025–35. [
PubMed: 11513370]
Furmark TT. Common changes in cerebral blood flow in patients with social phobia treated with citalopram or cognitive-behavioral therapy.
Archives of General Psychiatry. 2002;59:425–33. [
PubMed: 11982446]
Furmark T, Appel L, Michelgård A, Wahlstedt K, Ahs F, Zancan S, et al. Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo.
Biological Psychiatry. 2005;58:132–42. [
PubMed: 16038684]
Furmark T, Carlbring P, Hedman E, Sonnenstein A, Clevberger P, Bohman B, et al. Guided and unguided self-help for social anxiety disorder: randomised controlled trial.
British Journal of Psychiatry. 2009;195:440–47. [
PubMed: 19880935]
Fyer AJ, Mannuzza S, Chapman TF, Martin LY, Klein DF. Specificity in familial aggregation of phobic disorders.
Archives of General Psychiatry. 1995;52:564–73. [
PubMed: 7598633]
Gallagher HM, Rabian BA, McCloskey MS. A brief group cognitive-behavioral intervention for social phobia in childhood.
Journal of Anxiety Disorders. 2004;18:459–79. [
PubMed: 15149708]
Gelernter CS. A comparison of cognitive-behavioral and pharmacological treatments for social phobia. Dissertation Abstracts International. 1990;50:3156.
Gelernter CS, Uhde TW, Cimbolic P, Arnkoff DB, Vittone BJ, Tancer ME, et al. Cognitive-behavioral and pharmacological treatments of social phobia: a controlled study.
Archives of General Psychiatry. 1991;48:938–45. [
PubMed: 1929764]
General Medical Council. Good Practice in Prescribing and Managing Medicines and Devices. London: General Medical Council; 2013.
Gilroy LJ, Kirkby KC, Daniels BA, Menzies RG, Montgomery IM. Controlled comparison of computer-aided vicarious exposure versus live exposure in the treatment of spider phobia. Behavior Therapy. 2000;31:733–44.
GlaxoSmithKline. A randomized, double-blind, fixed dose comparison of 20, 40, and 60 mg daily of paroxetine and placebo in the treatment of generalized social phobia. GSK Clinical Study Register. 1997
GlaxoSmithKline. A randomized, double-blind, parallel-group, placebo-controlled, forced-dose titration study evaluating the efficacy and safety of a new chemical entity (NCE) and paroxetine in subjects with social anxiety disorder. GSK Clinical Study Register. 2006
Goldin PR, Ziv M, Jazaieri H, Werner K, Kraemer H, Heimberg RG, et al. Cognitive reappraisal self-efficacy mediates the effects of individual cognitive-behavioral therapy for social anxiety disorder.
Journal of Clinical and Consulting Psychology. 2012. in press. [
PMC free article: PMC3424305] [
PubMed: 22582765]
Gould R, Buckminster S, Pollack M, Otto M, Yap L. Cognitive-behavioral and pharmacological treatment for social phobia: a meta-analysis. Clinical Psychology Science and Practice. 1997;4:291–306.
Granado LC, Ranvaud R, Pelaez JR. A spiderless arachnophobia therapy: comparison between placebo and treatment groups and six-month follow-up study.
Neural Plasticity. 2007;2007:10241. [
PMC free article: PMC1940059] [
PubMed: 17713595]
Grant B, Hasin D, Blanco C, Stinson F, Chou S, Goldstein RB. The epidemiology of social anxiety disorder in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions.
Journal of Clinical Psychiatry. 2005;11:1351–61. [
PubMed: 16420070]
Grant BF, Stinson FS, Hasin DS, Dawson DA, Chou SP, Ruan WJ, et al. Prevalence, correlates, and comorbidity of bipolar I disorder and axis I and II disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions.
Journal of Clinical Psychiatry. 2005;66:1205–15. [
PubMed: 16259532]
Greenhill LL. A multisite treatment of anxiety disorders; 152nd Annual Meeting of the American Psychiatric Association; Washington, DC. 15–20 May, 1999.
Gregorian RS, Golden KA, Bahce A, Goodman C, Kwong WJ, Khan ZM. Antidepressant-induced sexual dysfunction.
The Annals of Pharmacotherapy. 2002;36:1577–89. [
PubMed: 12243609]
Greist JH, Liu-Dumaw M, Schweizer E, Feltner D. Efficacy of pregabalin in preventing relapse in patients with generalized social anxiety disorder: results of a double-blind, placebo-controlled 26–week study.
International Clinical Psychopharmacology. 2011;26:243–51. [
PubMed: 21734588]
Gruber K, Moran PJ, Roth WT, Taylor CB. Computer-assisted cognitive behavioral group therapy for social phobia. Behavior Therapy. 2001;32:155–65.
Guastella AJ, Richardson R, Lovibond PF, Rapee RM, Gaston JE, Mitchell P, et al. A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder.
Biological Psychiatry. 2008;63:544–49. [
PubMed: 18179785]
Guastella AJ, Howard AL, Dadds MR, Mitchell P, Carson DS. A randomized controlled trial of intranasal oxytocin as an adjunct to exposure therapy for social anxiety disorder.
Psychoneuroendocrinology. 2009;34:917–23. [
PubMed: 19246160]
Gunnell D, Saperia J, Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review.
BMJ. 2005;330:385. [
PMC free article: PMC549105] [
PubMed: 15718537]
Haddad PM. Antidepressant discontinuation syndromes: clinical relevance, prevention and management.
Drug Safety. 2001;24:183–97. [
PubMed: 11347722]
Hassan A. Doctoral dissertation. University of Leeds; 1992. A comparison of computer-based symbolic modelling and conventional methods in the treatment of spider phobia.
Haug TTB. Exposure therapy and sertraline in social phobia: 1-year follow-up of a randomised controlled trial.
British Journal of Psychiatry. 2003;182:312–18. [
PubMed: 12668406]
Hayes BB. Comparing the effectiveness of cognitive-behavioral group therapy with and without motivational interviewing at reducing the social anxiety, alcohol consumption, and negative consequences of socially anxious college students. Dissertation Abstracts International: Section B: The Sciences and Engineering. 2006;67
Heading K, Kirkby KC, Martin F, Daniels BA, Gilroy LJ, Menzies RG. Controlled comparison of single-session treatments for spider phobia: live graded exposure alone versus computer-aided vicarious exposure. Behaviour Change. 2001;18:103–13.
Healey D. The emergence of antidepressant induced suicidality. Primary Care Psychiatry. 2003;6:23–28.
Hedman E, Andersson E, Ljotsson B, Andersson G, Ruck C, Lindefors N. Cost-effectiveness of internet-based cognitive behavior therapy vs. cognitive behavioral group therapy for social anxiety disorder: results from a randomized controlled trial.
Behaviour Research and Therapy. 2011;49:729–36. [
PubMed: 21851929]
Hedman E, Andersson G, Ljotsson B, Andersson E, Ruck C, Mortberg E, et al. Internet-based cognitive behavior therapy vs. cognitive behavioral group therapy for social anxiety disorder: a randomized controlled non-inferiority trial.
PLoS ONE. 2011;6:e18001. [
PMC free article: PMC3070741] [
PubMed: 21483704]
Hedman E, Furmark T, Carlbring P, Ljotsson B, Ruck C, Lindefors N, et al. A 5–year follow-up of internet-based cognitive behavior therapy for social anxiety disorder.
Journal of Medical Internet Research. 2011;13 [
PMC free article: PMC3221374] [
PubMed: 21676694]
Heeren A, Reese HE, McNally RJ, Philippot P. Attention training toward and away from threat in social phobia: effects on subjective, behavioral, and physiological measures of anxiety.
Behaviour Research and Therapy. 2012;50:30–9. [
PubMed: 22055280]
Heideman PW. Combining cognitive behavioral therapy with an alcohol intervention to reduce alcohol problems among socially anxious college students. Dissertation Abstracts International: Section B: The Sciences and Engineering. 2008;69
Heimberg RG. Final Progress Report – NIMH Grant R01MH064481 CBT Augmentation of Paroxetine for Social Anxiety. 2012. in press.
Heimberg RG, Dodge CS, Hope DA, Kennedy CR, Zollo LJ, Becker RE. Cognitive behavioral group treatment for social phobia: comparison with a credible placebo control. Cognitive Therapy and Research. 1990;14:1–23.
Heimberg RG, Horner KJ, Juster HR, Safren SA, Brown EJ, Schneier FR, et al. Psychometric properties of the Liebowitz Social Anxiety Scale.
Psychological Medicine. 1999;29:199–212. [
PubMed: 10077308]
Heimberg RG, Juster HR, Hope DA, Mattia JI. Cognitive behavioral group treatment for social phobia: description, case presentation and empirical support. In: Stein MB, editor. Social Phobia: Clinical and Research Perspectives. Washington, DC: American Psychiatric Press; 1995. pp. 293–321.
Heimberg RG, Liebowitz MR, Hope DA, Schneier FR, Holt CS, Welkowitz LA, et al. Cognitive behavioral group therapy vs phenelzine therapy for social phobia 12–week outcome.
Archives of General Psychiatry. 1998;55:1133–41. [
PubMed: 9862558]
Heimberg RG, Salzman DG, Holt CS, Blendell KA. Cognitive-behavioral group treatment for social phobia: effectiveness at five-year followup. Cognitive Therapy and Research. 1993;17:325–39.
Hellstrom K, Ost LG. One-session therapist directed exposure vs two forms of manual directed self-exposure in the treatment of spider phobia.
Behaviour Research and Therapy. 1995;33:959–65. [
PubMed: 7487856]
Herbert JD, Gaudiano BA, Rheingold AA, Moitra E, Myers VH, Dalrymple KL, et al. Cognitive behavior therapy for generalized social anxiety disorder in adolescents: a randomized controlled trial.
Journal of Anxiety Disorders. 2009;23:167–77. [
PMC free article: PMC4356535] [
PubMed: 18653310]
Herbert JD, Gaudiano BA, Rheingold AA, Myers VH, Dalrymple K, Nolan EM. Social skills training augments the effectiveness of cognitive behavioral group therapy for social anxiety disorder. Behavior Therapy. 2005;36:125–38.
Herbert JD, Rheingold AA, Gaudiano BA, Myers VH. Standard versus extended cognitive behavior therapy for social anxiety disorder: a randomized-controlled trial. Behavioural and Cognitive Psychotherapy. 2004;32:131–47.
Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. The Cochrane Collaboration; 2011. [updated March 2011 ]
Hindmarch I, Kimber S, Cockle SM. Abrupt and brief discontinuation of antidepressant treatment: effects on cognitive function and psychomotor performance.
International Clinical Psychopharmacology. 2000;15:305–18. [
PubMed: 11110006]
Hoffart A, Borge FM. Psychotherapy for social phobia: how do alliance and cognitive process interact to produce outcome?
Psychotherapy Research. 2012;22 [
PubMed: 22103774]
Hoffart AB. Change processes in residential cognitive and interpersonal psychotherapy for social phobia: a process-outcome study.
Behavior Therapy. 2009;40:10–22. [
PubMed: 19187813]
Hoffart AB. The role of common factors in residential cognitive and interpersonal therapy for social phobia: a process-outcome study.
Psychotherapy Research. 2009;19:54–67. [
PubMed: 18846473]
Hofmann SG, Meuret AE, Smits JAJ, Simon NM, Pollack MH, Eisenmenger K, et al. Augmentation of exposure therapy with D-cycloserine for social anxiety disorder.
Archives of General Psychiatry. 2006;63:298–304. [
PubMed: 16520435]
Hofmann SG, Smits JAJ, Rosenfield D, Simon N, Otto M, Meuret A, et al. D-cycloserine as an augmentation strategy for cognitive behavioral therapy for anxiety disorders.
American Journal of Psychiatry. 2013;170:751–58. [
PMC free article: PMC4058999] [
PubMed: 23599046]
Hope DA, Heimberg RG, Bruch MA. Dismantling cognitive-behavioral group therapy for social phobia.
Behaviour Research and Therapy. 1995;33:637–50. [
PubMed: 7654156]
Hope DA, Heimberg RG, Turk CL. Therapist guide for managing social anxiety: a cognitive-behavioral therapy approach. New York: Oxford University Press; 2006.
Hudson JL, Rapee RM, Deveney C, Schniering CA, Lyneham HJ, Bovopoulos N. Cognitive-behavioral treatment versus an active control for children and adolescents with anxiety disorders: a randomized trial.
Journal of the American Academy of Child and Adolescent Psychiatry. 2009;48:533–44. [
PubMed: 19318990]
Hudson JL, Rapee RM, Lyneham H, Wuthrich V, Schneiring CA. World Congress of Behavioural and Cognitive Therapies. Boston, MA: 2010. Treatment outcome for children with social phobia.
Hudson JL, Newall C, Rapee RM, Lyneham HJ, Schniering CA, Wuthrich VM, et al. The impact of brief parental anxiety management on child anxiety treatment outcomes: a controlled trial.
Journal of Clinical Child and Adolescent Psychology. 2013. Published online: 11 July. [
PMC free article: PMC4037847] [
PubMed: 23845064]
Issakidis C, Sanderson K, Corry J, Andrews G, Lapsley H. Modelling the population cost-effectiveness of current and evidence-based optimal treatment for anxiety disorders.
Psychological Medicine. 2004;34:19–35. [
PubMed: 14971624]
Jackson SW. The listening healer in the history of psychological healing.
The American Journal of Psychiatry. 1992;149:1623–32. [
PubMed: 1443239]
Jacobson NS, Truax P. Clinical significance: a statistical approach to defining meaningful change in psychotherapy research.
Journal of Consulting and Clinical Psychology. 1991;59:12–19. [
PubMed: 2002127]
Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?
Controlled Clinical Trials. 1996;17:1–12. [
PubMed: 8721797]
James A, James G, Cowdrey F, Soler A, Choke A. Cognitive behavioural therapy for anxiety disorders in children and adolescents.
Cochrane Database of Systematic Reviews. 2013;6 CD004690. [
PubMed: 23733328]
Jazaieri H, Goldin P, Werner K, Ziv M, Gross J. A randomized trial of MBSR versus aerobic exercise for social anxiety disorder.
Journal of Clinical Psychology. 2012;68:715–31. [
PMC free article: PMC4136448] [
PubMed: 22623316]
Johnston L, Titov N, Andrews G, Spence J, Dear BF. A RCT of a transdiagnostic internet-delivered treatment for three anxiety disorders: examination of support roles and disorder-specific outcomes.
PLoS ONE. 2011;6:e28079. [
PMC free article: PMC3223218] [
PubMed: 22132216]
Joint Formulary Committee. British National Formulary. 65th edn. London: BMJ Group and Pharmaceutical Press; 2013.
Judge R, Parry MG, Quail D, Jacobson JG. Discontinuation symptoms: comparison of brief interruption in fluoxetine and paroxetine treatment.
International Clinical Psychopharmacology. 2002;17:217–25. [
PubMed: 12177584]
Kaltenthaler E, Brazier J, De Nigris E, Tumur I, Ferriter M, Beverley C, et al. Computerised cognitive behaviour therapy for depression and anxiety update: a systematic review and economic evaluation.
Health Technology Assessment. 2006;10:1–168. [
PubMed: 16959169]
Kasper S, Loft H, Smith JR. Escitalopram is efficacious and well tolerated in the treatment of social anziety disorder; 155th Annual Meeting of the American Psychiatric Association; Philadelphia, PA. 18–May, 2002.
Kasper S, Stein DJ, Loft H, Nil R. Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study.
British Journal of Psychiatry. 2005;186:222–26. [
PubMed: 15738503]
Katon WRB. Anxiety disorders: efficient screening is the first step in improving outcomes.
Annals of Internal Medicine. 2007;146:390–91. [
PubMed: 17339624]
Katzelnick DJ, Kobak KA, DeLeire T, Henk HJ, Greist JH, Davidson JR, et al. Impact of generalized social anxiety disorder in managed care.
The American Journal of Psychiatry. 2001;158:1999–2007. [
PubMed: 11729016]
Keller MB. Citalopram therapy for depression: a review of 10 years of European experience and data from U.S. clinical trials.
Journal of Clinical Psychiatry. 2000;61:896–908. [
PubMed: 11206593]
Kendler KS, Neale MC, Kessler RC, Heath AC, Eaves LJ. The genetic epidemiology of phobias in women. The interrelationship of agoraphobia, social phobia, situational phobia, and simple phobia.
Archives of General Psychiatry. 1992;49:273–81. [
PubMed: 1558461]
Kendler KS, Karkowski LM, Prescott CA. Fears and phobias: reliability and heritability.
Psychological Medicine. 1999;29:539–53. [
PubMed: 10405076]
Kerns CM, Klugman J, Kendall PC. Cognitive behavioral therapy for youth with social phobia: differential short and long-term treatment outcomes.
2012 Under review. [
PubMed: 23474911]
Kessler RC, Stein MB, Berglund P. Social phobia subtypes in the National Comorbidity Survey.
American Journal of Psychiatry. 1998;155:613–19. [
PubMed: 9585711]
Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication.
Archives of General Psychiatry. 2005;62:593–602. [
PubMed: 15939837]
Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12–month DSM-IV disorders in the National Comorbidity Survey Replication.
Archives of General Psychiatry. 2005;62:617–27. [
PMC free article: PMC2847357] [
PubMed: 15939839]
Knijnik DZ, Kapczinski F, Chachamovich E, Margis R, Eizirik CL. Psychodynamic group treatment for generalized social phobia.
Revista Brasileira de Psiquiatria. 2004;26:77–81. [
PubMed: 15517057]
Knijnik DZ, Blanco C, Salum GA, Moraes CU, Mombach C, Almeida E, et al. A pilot study of clonazepam versus psychodynamic group therapy plus clonazepam in the treatment of generalized social anxiety disorder.
European Psychiatry. 2008;23:567–74. [
PMC free article: PMC4389899] [
PubMed: 18774274]
Kobak KA, Greist JH, Jefferson JW, Katzelnick DJ. Fluoxetine in social phobia: a double-blind, placebo-controlled pilot study.
Journal of Clinical Psychopharmacology. 2002;22:257–62. [
PubMed: 12006895]
Kobak KA, Taylor LV, Warner G, Futterer R. St. John's wort versus placebo in social phobia: results from a placebo-controlled pilot study.
Journal of Clinical Psychopharmacology. 2005;25:51–58. [
PubMed: 15643100]
Konnopka A, Leichsenring F, Leibing E, Konig HH. Cost-of-illness studies and cost-effectiveness analyses in anxiety disorders: a systematic review.
Journal of Affective Disorders. 2009;114:14–31. [
PubMed: 18768222]
Koszycki D, Benger M, Shlik J, Bradwejn J. Randomized trial of a meditation-based stress reduction program and cognitive behavior therapy in generalized social anxiety disorder.
Behaviour Research and Therapy. 2007;45:2518–26. [
PubMed: 17572382]
Kroenke KS. The Patient Health Questionnaire Somatic, Anxiety, and Depressive Symptom Scales: a systematic review.
General Hospital Psychiatry. 2010;32:345–59. [
PubMed: 20633738]
Kroenke K, Spitzer RL, Williams JB, Monahan PO, Lowe B. Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection.
Annals of Internal Medicine. 2007;146:317–25. [
PubMed: 17339617]
Kumar R, Pitts C, Carpenter D. Response to paroxetine is maintained during continued treatment in patients with social anxiety disorder. European Neuropsychopharmacology. 1999;9:S312.
Kupper N, Denollet J, Kupper N, Denollet J. Social anxiety in the general population: introducing abbreviated versions of SIAS and SPS.
Journal of Affective Disorders. 2012;136:90–98. [
PubMed: 21903277]
Lader M, Stender K, Bürger V, Nil R. Efficacy and tolerability of escitalopram in 12–and 24–week treatment of social anxiety disorder: Randomised, double-blind, placebo-controlled, fixed-dose study.
Depression and Anxiety. 2004;19:241–48. [
PubMed: 15274173]
Lambert MJ, Whipple JL, Hawkins EJ, Vermeersch DA, Nielsen SL, Smart DW. Is it time for clinicians to routinely track patient outcome? A meta-analysis. Clinical Psychology: Science and Practice. 2003;10:288–301.
Lau WY, Chan CK, Li JC, Au TK. Effectiveness of group cognitive-behavioral treatment for childhood anxiety in community clinics.
Behaviour Research and Therapy. 2010;48:1067–77. [
PubMed: 20696421]
Layard R, Bell S, Clark DM, Knapp M, Meacher M, Priebe S.
The Depression Report: A New Deal for Depression and Anxiety Disorders. Centre for Economic Performance Report. London: London School of Economics; 2006. Available from:
http//cep.lse.ac.uk.
Lecrubier Y. Comorbidity in social anxiety disorder: impact on disease burden and management.
Journal of Clinical Psychiatry. 1998;59(Suppl. 17):33–8. [
PubMed: 9811428]
Ledley DRH. Impact of depressive symptoms on the treatment of generalized social anxiety disorder.
Depression and Anxiety. 2005;22:161–67. [
PubMed: 16175565]
Ledley DR, Heimberg RG, Hope DA, Hayes SA, Zaider TI, Dyke MV, et al. Efficacy of a manualized and workbook-driven individual treatment for social anxiety disorder.
Behavior Therapy. 2009;40:414–24. [
PubMed: 19892086]
Leichsenring F, Hoyer J, Beutel M, Herpertz S, Hiller W, Irle E, et al. The social phobia psychotherapy research network - the first multicenter randomized controlled trial of psychotherapy for social phobia: rationale, methods and patient characteristics.
Psychotherapy and Psychosomatics. 2009;78:35–41. [
PubMed: 18852500]
Leichsenring F, Salzer S, Beutel ME, von Consbruch K, Herpertz S, Hiller W, et al. SOPHO-NET - A research network on psychotherapy for social phobia.
PPmP - Psychotherapie Psychosomatik Medizinische Psychologie. 2009;59:117–23. [
PubMed: 19350471]
Lejoyeux M, Ades J. Antidepressant discontinuation: a review of the literature.
Journal of Clinical Psychiatry. 1997;58(Suppl. 7):11–5. discussion 16. [
PubMed: 9219488]
Lejoyeux M, Ades J, Mourad I. Antidepressant withdrawal syndrome: recognition, prevention and management. CNS Drugs. 1996;5:278–92.
Lepola U, Bergtholdt B, St Lambert J, Davy KL, Ruggiero L. Controlled-release paroxetine in the treatment of patients with social anxiety disorder.
Journal of Clinical Psychiatry. 2004;65:222–29. [
PubMed: 15003077]
Lewis G, Anderson L, Araya R. Self-help Interventions for Mental Health Problems. Department of Health; 2003.
Lieb R, Wittchen HU, Hofler M, Fuetsch M, Stein MB, Merikangas KR. Parental psychopathology, parenting styles, and the risk of social phobia in offspring: a prospective-longitudinal community study.
Archives of General Psychiatry. 2000;57:859–66. [
PubMed: 10986549]
Liebowitz MR. Social phobia.
Modern Problems of Pharmacopsychiatry. 1987;22:141–73. [
PubMed: 2885745]
Liebowitz MRG. Pharmacotherapy of social phobia: an interim report of a placebo-controlled comparison of phenelzine and atenolol.
Journal of Clinical Psychiatry. 1988;49:252–57. [
PubMed: 3292516]
Liebowitz MRH. Cognitive-behavioral group therapy versus phenelzine in social phobia: long term outcome.
Depression and Anxiety. 1999;10:89–98. [
PubMed: 10604081]
Liebowitz M. Efficacy of venlafaxine XR in generalized social anxiety disorder. International Journal of Neuropsychopharmacology. 2002;5:211.
Liebowitz MR, Schneier F, Campeas R, Gorman J, Fyer A, Hollander E, et al. Phenelzine and atenolol in social phobia.
Psychopharmacology Bulletin. 1990;26:123–25. [
PubMed: 2196620]
Liebowitz MR, Schneier F, Campeas R, Hollander E, Hatterer J, Fyer A, et al. Phenelzine vs atenolol in social phobia: a placebo-controlled comparison.
Archives of General Psychiatry. 1992;49:290–300. [
PubMed: 1558463]
Liebowitz MR, Heimberg RG, Schneier FR, Hope DA, Davies S, Holt CS, et al. Cognitive-behavioral group therapy versus phenelzine in social phobia: long-term outcome.
Depression and Anxiety. 1999;10:89–98. [
PubMed: 10604081]
Liebowitz M, DeMartinis N, Weihs K, Chung H, Clary C. Results from a randomized, double-blind, multicenter trial of sertaline in the treatment of moderate-to-severe social phobia (social anxiety disorder). European Neuropsychopharmacology. 2002;12:S352.
Liebowitz MR, Stein MB, Tancer M, Carpenter D, Oakes R, Pitts CD. A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder.
Journal of Clinical Psychiatry. 2002;63:66–74. [
PubMed: 11838629]
Liebowitz MR, DeMartinis NA, Weihs K, Londborg PD, Smith WT, Chung H, et al. Efficacy of sertraline in severe generalized social anxiety disorder: results of a double-blind, placebo-controlled study.
Journal of Clinical Psychiatry. 2003;64:785–92. [
PubMed: 12934979]
Liebowitz MR, Gelenberg AJ, Munjack D. Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder.
Archives of General Psychiatry. 2005;62:190–98. [
PubMed: 15699296]
Liebowitz MR, Mangano RM, Bradwejn J, Asnis G. A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder.
Journal of Clinical Psychiatry. 2005;66:238–47. [
PubMed: 15705011]
Lipsitz JD, Gur M, Vermes D, Petkova E, Cheng J, Miller N, et al. A randomized trial of interpersonal therapy versus supportive therapy for social anxiety disorder.
Depression and Anxiety. 2008;25:542–53. [
PubMed: 17941096]
Lipsitz JD, Markowitz JC, Cherry S. Manual for interpersonal psychotherapy of social phobia. New York: Columbia University College of Physicians; 1997.
Lipsitz JD, Schneier FR. Social phobia. Epidemiology and cost of illness.
Pharmaco-Economics. 2000;18:23–32. [
PubMed: 11010601]
Lott M, Greist JH, Jefferson JW, Kobak KA, Katzelnick DJ, Katz RJ, et al. Brofaromine for social phobia: a multicenter, placebo-controlled, double-blind study.
Journal of Clinical Psychopharmacology. 1997;17:255–60. [
PubMed: 9241003]
Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons.
Statistics in Medicine. 2004;23:3105–24. [
PubMed: 15449338]
Lunn DJ, Thomas A, Best N, Spiegelhalter D. WinBUGS – a Bayesian modelling framework: concepts, structure, and extensibility. Statistics and Computing. 2000;10:325–37.
Lyneham HJ, Abbott MJ, Rapee RM, Sburlati ES. Parent group supported bibliotherapy for child anxiety: a randomised controlled trial comparing standard group treatment and waitlist. 2013. (in preparation)
Macaskill P, Gatsonis C, Deeks JJ, Harbord RM, Takwoingi Y. Chapter 10: Analysing and presenting results. In: Deeks JJ, Bossuyt PM, Gatsonis C, editors. Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy. Version 1.0. The Cochrane Collaboration; 2010.
Magee WJ, Eaton WW, Wittchen HU, McGonagle KA, Kessler RC. Agoraphobia, simple phobia, and social phobia in the National Comorbidity Survey.
Archives of General Psychiatry. 1996;53:159–68. [
PubMed: 8629891]
Mann T. Clinical Guidelines: Using Clinical Guidelines to Improve Patient Care Within the NHS. London: NHS Executive; 1996.
March JS, Parker JD, Sullivan K, Stallings P, Conners CK. The Multidimensional Anxiety Scale for Children (MASC): factor structure, reliability, and validity.
Journal of the American Academy of Child and Adolescent Psychiatry. 1997;36:554–65. [
PubMed: 9100431]
March JS, Entusah AR, Rynn M, Albano AM, Tourian KA. A randomized controlled trial of venlafaxine ER versus placebo in pediatric social anxiety disorder.
Biological Psychiatry. 2007;62:1149–54. [
PubMed: 17553467]
March S, Spence SH, Donovan CL. The efficacy of an internet-based cognitive-behavioral therapy intervention for child anxiety disorders.
Journal of Pediatric Psychology. 2009;34:474–87. [
PubMed: 18794187]
Marks IM. Fears and Phobias. London: Heinemann; 1975.
Marks IM. Behavioral concepts and treatments of neuroses. Behavioral Psychotherapy. 1981;9:137–54.
Marks IM, Gelder MG. A controlled retrospective study of behaviour therapy in phobic patients.
The British Journal of Psychiatry. 1965;111:561–73. [
PubMed: 14344917]
Marks IM, Mathews AM. Brief standard self-rating for phobic patients.
Behaviour Research and Therapy. 1979;17:263–67. [
PubMed: 526242]
Marks IM, Kenwright M, McDonough M, Whittaker M, Mataix-Cols D. Saving clinicians' time by delegating routine aspects of therapy to a computer: a randomized controlled trial in phobia/panic disorder.
Psychological Medicine. 2004;34:9–17. [
PubMed: 14971623]
Marques L, Porter E, Keshaviah A, Pollack MH, Van Ameringen M, Stein MB, et al. Avoidant personality disorder in individuals with generalized social anxiety disorder: what does it add?
Journal of Anxiety Disorders. 2012;26:665–72. [
PMC free article: PMC3417304] [
PubMed: 22705954]
Martinez C, Rietbrock S, Wise L, Ashby D, Chick J, Moseley J, et al. Antidepressant treatment and the risk of fatal and non-fatal self harm in first episode depression: nested case-control study.
BMJ. 2005;330:389. [
PMC free article: PMC549107] [
PubMed: 15718538]
Masia-Warner CK. School-based intervention for adolescents with social anxiety disorder: results of a controlled study.
Journal of Abnormal Child Psychology. 2005;33:707–22. [
PubMed: 16328746]
Masia-Warner C, Fisher PH, Shrout PE, Rathor S, Klein RG. Treating adolescents with social anxiety disorder in school: an attention control trial.
Journal of Child Psychology and Psychiatry. 2007;48:676–86. [
PubMed: 17593148]
Matthews AJ, Wong ZH, Scanlan JD, Kirkby KC. Online exposure for spider phobia: continuous versus intermittent exposure. Behaviour Change. 2011;28:143.
Mattick RP, Clarke JC. Development and validation of measures of social phobia scrutiny fear and social interaction anxiety.
Behaviour Research and Therapy. 1998;36:455–70. [
PubMed: 9670605]
Mattick RP, Peters L. Treatment of severe social phobia: effects of guided exposure with and without cognitive restructuring.
Journal of Consulting and Clinical Psychology. 1988;56:251–60. [
PubMed: 2897386]
Mattick RP, Peters L, Clarke JC. Exposure and cognitive restructuring for social phobia: a controlled study. Behavior Therapy. 1989;20:3–23.
McEvoy PM, Perini SJ, McEvoy PM, Perini SJ. Cognitive behavioral group therapy for social phobia with or without attention training: a controlled trial.
Journal of Anxiety Disorders. 2009;23:519–28. [
PubMed: 19059753]
McManus F, Clark DM, Grey N, Wild J, Hirsch C, Fennell M, et al. A demonstration of the efficacy of two of the components of cognitive therapy for social phobia.
Journal of Anxiety Disorders. 2009;23:496–503. [
PubMed: 19081225]
McManus S, Meltzer H, Brugha T, Bebbington P, Jenkins R. Adult Psychiatric Morbidity in England, 2007: Results of a Household Survey. Leeds: NHS Information Centre; 2009.
McQuaid JR, Stein MB, McCahill M, Laffaye C, Ramel W. Use of brief psychiatric screening measures in a primary care sample.
Depression and Anxiety. 2000;12:21–9. [
PubMed: 10999242]
Means-Christensen AJ, Sherbourne CD, Roy-Byrne PP, Craske MG, Stein MB. Using five questions to screen for five common mental disorders in primary care: diagnostic accuracy of the Anxiety and Depression Detector.
General Hospital Psychiatry. 2006;28:108–18. [
PubMed: 16516060]
Meijer WE, Bouvy ML, Heerdink ER, Urquhart J, Leufkens HG. Spontaneous lapses in dosing during chronic treatment with selective serotonin reuptake inhibitors.
The British Journal of Psychiatry. 2001;179:519–22. [
PubMed: 11731355]
Melfsen S, Kühnemund M, Schwieger J, Warnke A, Stadler C, Poustka F, et al. Cognitive behavioral therapy of socially phobic children focusing on cognition: a randomised wait-list control study.
Child and Adolescent Psychiatry and Mental Health. 2011;5:5. [
PMC free article: PMC3058082] [
PubMed: 21356037]
Meltzer H, Gill B, Petticrew M, Hinds K. OPCS Surveys of Psychiatric Morbidity in Great Britain, Report 2: Physical Complaints, Service Use and Treatment of Adults with Psychiatric Disorders. London: HMSO; 1995.
MHRA.
Updated Prescribing Advice for Venlafaxine (Efexor/Efexor XL). 2006. Available at
http://wwwmhragovuk/MHRA. Citalopram and escitalopram: QT interval prolongation—new maximum daily dose restrictions (including in elderly patients), contraindications, and warnings. Drug Safety Update. Dec 5, 2011.
Michail M, Birchwood M. Social anxiety disorder in first-episode psychosis: incidence, phenomenology and relationship with paranoia.
British Journal of Psychiatry. 2009;195:234–41. [
PubMed: 19721113]
Michelson D, Fava M, Amsterdam J, Apter J, Londborg P, Tamura R, et al. Interruption of selective serotonin reuptake inhibitor treatment. Double-blind, placebo-controlled trial.
The British Journal of Psychiatry. 2000;176:363–8. [
PubMed: 10827885]
Montgomery SA, Kennedy SH, Burrows GD, Lejoyeux M, Hindmarch I. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study.
International Clinical Psychopharmacology. 2004;19:271–80. [
PubMed: 15289700]
Montgomery SA, Nil R, Dürr-Pal N, Loft H, Boulenger JP. A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder.
Journal of Clinical Psychiatry. 2005;66:1270–78. [
PubMed: 16259540]
Morgan H, Raffle C. Does reducing safety behaviours improve treatment response in patients with social phobia?
The Australian and New Zealand Journal of Psychiatry. 1999;33:503–10. [
PubMed: 10483844]
Morgan O, Griffiths C, Baker A, Majeed A. Fatal toxicity of antidepressants in England and Wales, 1993–2002.
Health Statistics Quarterly/Office for National Statistics. 2004:18–24. [
PubMed: 15704381]
Mortberg EB. Temperament and character dimensions in patients with social phobia: Patterns of change following treatments?
Psychiatry Research. 2007;152:81–90. [
PubMed: 17328961]
Mortberg E, Clark DM. Intensive group cognitive therapy and individual cognitive therapy for social phobia: sustained improvement at 5-year follow-up.
Journal of Anxiety Disorders. 2011;25:994–1000. [
PubMed: 21763101]
Mortberg E, Clark DM, Sundin O, Wistedt AA. Intensive group cognitive treatment and individual cognitive therapy vs. treatment as usual in social phobia: a randomized controlled trial.
Acta Psychiatrica Scandinavica. 2007;115:142–54. [
PubMed: 17244178]
Mowrer OH. On the dual nature of learning: a re-interpretation of ‘conditioning’ and ‘problem-solving’ Harvard Educational Review. 1947;17:102–48.
Mowrer OH. Learning Theory and Behavior. Hoboken, NJ: John Wiley & Sons; 1960.
Muehlbacher M, Nickel MK, Nickel C, et al. Mirtazapine treatment of social phobia in women: a randomized, double-blind, placebo-controlled study.
Journal of Clinical Psychopharmacology. 2005;25:580–83. [
PubMed: 16282842]
Müller BH, Kull S, Wilhelm FH, Michael T. One-session computer-based exposure treatment for spider-fearful individuals: efficacy of a minimal self-help intervention in a randomised controlled trial.
Journal of Behavior Therapy and Experimental Psychiatry. 2011;42:179–84. [
PubMed: 21315879]
Mulkens S, Bögels SM, de Jong PJ, Louwers J. Fear of blushing: effects of task concentration training versus exposure in vivo on fear and physiology.
Journal of Anxiety Disorders. 2001;15:413–32. [
PubMed: 11583074]
Munjack DJ, Baltazar PL, Bohn PB, Cabe DD, Appleton AA. Clonazepam in the treatment of social phobia: a pilot study.
Journal of Clinical Psychiatry. 1990;51:35–40. [
PubMed: 2186023]
Muris P, Merckelbach H, Kindt M, Bogels S, Dreessen L, van Dorp C, et al. The utility of Screen for Child Anxiety Related Emotional Disorders (SCARED) as a tool for identifying children at high risk for prevalent anxiety disorders. Anxiety Stress and Coping. 2001;14:265–83.
Mykletun A, Bjerkeset O, Overland S, Prince M, Dewey M, Stewart R. Levels of anxiety and depression as predictors of mortality: the HUNT study.
British Journal of Psychiatry. 2009;195:118–25. [
PubMed: 19648541]
Nardi AE, Lopes FL, Valenca AM, Freire RC, Nascimento I, Veras AB, et al. Double-blind comparison of 30 and 60 mg tranylcypromine daily in patients with panic disorder comorbid with social anxiety disorder.
Psychiatry Research. 2010;175:260–5. [
PubMed: 20036427]
NCCMH.
Depression in Children and Young People: Identification and Management in Primary, Community and Secondary Care. London: The British Psychological Society & The Royal College of Psychiatrists; 2005. [Full guideline] [
PubMed: 21834190]
NCCMH. Depression: The Treatment and Management of Depression in Adults. Updated edition. London & Leicester: The British Psychological Society and the Royal College of Psychiatrists; 2010. [Full guideline]
NCCMH.
Common Mental Health Disorders: Identification and Pathways to Care. Leicester & London: The British Psychological Society and the Royal College of Psychiatrists; 2011. [Full guideline] [
PubMed: 22536621]
NCCMH.
Generalised Anxiety Disorder in Adults: Management in Primary, Secondary and Community Care. Leicester & London: The British Psychological Society & the Royal College of Psychiatrists; 2011. [Full guideline] [
PubMed: 22536620]
NCCMH.
Service User Experience in Adult Mental Health: Improving the Experience of Care for People Using Adult NHS Mental Health Services. Leicester & London: The British Psychological Society & the Royal College of Psychiatrists; 2012. [Full guideline] [
PubMed: 26065056]
NCCMH.
Antisocial Behaviour and Conduct Disorders in Children and Young People: Recognition, Intervention and Management. London: The British Psychological Society and The Royal College of Psychiatrists; 2013. [
PubMed: 26065062]
Nepon J, Belik SL, Bolton J, Sareen J. The relationship between anxiety disorders and suicide attempts: findings from the National Epidemiologic Survey on Alcohol and Related Conditions.
Depression and Anxiety. 2010;27:791–8. [
PMC free article: PMC2940247] [
PubMed: 20217852]
Newman MG, Hofmann SG, Trabert W, Roth WT, Taylor CB. Does behavioral treatment of social phobia lead to cognitive changes? Behavior Therapy. 1994;25:503–17.
NHS Business Services Authority Prescription Pricing Division. Electronic Drug Tariff for England and Wales, February 2013. Compiled on behalf of the Department of Health; 2013.
NICE.
NICE clinical guideline 90. London: NICE; 2009. Depression in Adults: The Treatment and Management of Depression in Adults. Available from:
www.nice.org.uk/CG90. [NICE guideline]
NICE.
NICE clinical guideline 113. London: NICE; 2011. Generalised Anxiety Disorder and Panic Disorder (With or Without Agoraphobia) in Adults: Management in Primary, Secondary and Community Care. Available from:
www.nice.org.uk/CG113. [NICE guideline]
NICE.
NICE clinical guideline 136. London: NICE; 2011. Service User Experience in Adult Mental Health: Improving the Experience of Care for People Using Adult NHS Mental Health Services. Available from:
www.nice.org.uk/CG136. [NICE guideline]
NICE.
NICE clinical guideline 138. London: NICE; 2012. Patient Experience in Adult NHS Services: Improving the Experience of Care for People Using Adult NHS Services. Available from:
www.nice.org.uk/CG138. [NICE guideline]
Nordgreen T, Havik OE, Ost LG, Furmark T, Carlbring P, Andersson G. Outcome predictors in guided and unguided self-help for social anxiety disorder.
Behaviour Research and Therapy. 2012;50:13–21. [
PubMed: 22134140]
Norton PJ, Barrera TL. Transdiagnostic versus diagnosis-specific CBT for anxiety disorders: a preliminary randomized controlled noninferiority trial.
Depression and Anxiety. 2012;29:874–82. [
PMC free article: PMC3463777] [
PubMed: 22767410]
Noyes R Jr, Moroz G, Davidson JR, Liebowitz MR, Davidson A, Siegel J, et al. Moclobemide in social phobia: a controlled dose-response trial.
Journal of Clinical Psychopharmacology. 1997;17:247–54. [
PubMed: 9241002]
Nunnally JC. Psychometric Theory. 3rd edn. New York: McGraw-Hill Inc.; 1994.
Oei TP, Moylan A, Evans L. Validity and clinical utility of the Fear Questionnaire for anxiety-disorder patients. Psychological Assessment: A Journal of Consulting and Clinical Psychology. 1991;3:391.
Olivares-Olivares PJ, Rosa-Alcázar AI, Olivares-Rodríguez J. Does individual attention improve the effect of group treatment of adolescents with social phobia? International Journal of Clinical and Health Psychology. 2008;8:465–81.
Oosterbaan DB, van Balkom AJLM, Spinhoven P, van Oppen P, van Dyck R. Cognitive therapy versus moclobemide in social phobia: a controlled study. Journal of Clinical Psychology and Psychotherapy. 2001;35:889–900.
Osman A, Kopper BA, Barrios FX, Osman JR, Wade T. The Beck Anxiety Inventory: Reexamination of factor structure and psychometric properties.
Journal of Clinical Psychology. 1998;53:7–14. [
PubMed: 9120035]
Osório F, Crippa JA, Loureiro SR. A study of the discriminative validity of a screening tool (MINI-SPIN) for social anxiety disorder applied to Brazilian university students.
European Psychiatry. 2007;22:239–43. [
PubMed: 17346942]
Ost LG, Ferebee I, Furmark T. One-session group therapy of spider phobia: direct versus indirect treatments.
Behaviour Research and Therapy. 1997;35:721–32. [
PubMed: 9256515]
Ost LG, Alm T, Brandberg M, Breitholtz E. One vs five sessions of exposure and five sessions of cognitive therapy in the treatment of claustrophobia.
Behaviour Research and Therapy. 2001;39:167–83. [
PubMed: 11153971]
Otto MW, Pollack MH, Gould RA, Worthington JJ, McArdle ET, Rosenbaum JF. A comparison of the efficacy of clonazepam and cognitive-behavioral group therapy for the treatment of social phobia.
Journal of Anxiety Disorders. 2000;14:345–58. [
PubMed: 11043885]
Owen RT. Controlled-release fluvoxamine in obsessive-compulsive disorder and social phobia.
Drugs of Today. 2008;44:887–93. [
PubMed: 19198698]
Paediatric Formulary Committee. BNF for Children. London: BMJ Group, Pharmaceutical Press, and RCPCH Publications; 2012–2013.
Pande AC, Davidson JR, Jefferson JW, Janney CA, Katzelnick DJ, Weisler RH, et al. Treatment of social phobia with gabapentin: a placebo-controlled study.
Journal of Clinical Psychopharmacology. 1999;19:341–48. [
PubMed: 10440462]
Pande AC, Feltner DE, Jefferson JW, Davidson JR, Pollack M, Stein MB, et al. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study.
Journal of Clinical Psychopharmacology. 2004;24:141–49. [
PubMed: 15206660]
Patel A, Knapp M, Henderson J, Baldwin D. The economic consequences of social phobia.
Journal of Affective Disorders. 2002;68:221–33. [
PubMed: 12063150]
Pfizer. A 10-week, randomized, double-blind, placebo-controlled study of paroxetine and pregabalin in patients with social phobia (1008-081 and 1008-153). Web Synopsis Protocol 1008-081/153 - 21 June 2007 - Final. In press.
Piet J, Hougaard E, Hecksher MS, Rosenberg N. A randomized pilot study of mindfulness-based cognitive therapy and group cognitive-behavioral therapy for young adults with social phobia.
Scandinavian Journal of Psychology. 2010;51:403–10. [
PubMed: 20210911]
Pine DS, Cohen P, Gurley D, Brook J, Ma Y. The risk for early-adulthood anxiety and depressive disorders in adolescents with anxiety and depressive disorders.
Archives of General Psychiatry. 1998;55:56–64. [
PubMed: 9435761]
Polit DF, Beck CT, Owen SV. Is the CVI an acceptable indicator of content validity? Appraisal and recommendations.
Research in Nursing and Health. 2007;30:459–67. [
PubMed: 17654487]
Prasetyo J, Horacek J, Paskova B, Praskova H. Moclobemide and/or CBT in the treatment of social phobia: 6-months study; XII World Congress of Psychiatry; Yokohama, Japan. 9–24 August 2002.
Prasko JK. Pharmacotherapy and/or cognitive-behavioral therapy in the treatment of social phobia: control study with two year follow up. Ceska a Slovenska Psychiatrie. 2003;99:106–08.
Prasko J, Kosova J, Klaschka J, Seifertova D, Paskova H. Pharmacotherapy and psychotherapy in the treatment of social phobia: controlled study; XI World Congress of Psychiatry; Hamburg. 6–11 August 1999; p. 94. Abstracts.
Prasko J, Horacek J, Paskova B. Moclobemide and/or CBT in the treatment of social phobia; 32nd Congress of the British Association for Behavioural and Cognitive Psychotherapies; Manchester. 7–11 September 2004.
Prasko J, Dockery C, Horacek J, Houbova P, Kosova J, Klaschka J, et al. Moclobemide and cognitive behavioral therapy in the treatment of social phobia. A six-month controlled study and 24 months follow up.
Neuro Endocrinology Letters. 2006;27:473–81. [
PubMed: 16891998]
Randall CL, Johnson MR, Thevos AK, Sonne SC, Thomas SE, Willard SL, et al. Paroxetine for social anxiety and alcohol use in dual-diagnosed patients.
Depression and Anxiety. 2001;14:255–62. [
PubMed: 11754136]
Randall CL, Thomas S, Thevos AK. Concurrent alcoholism and social anxiety disorder: a first step toward developing effective treatments.
Alcoholism: Clinical and Experimental Research. 2001;25:210–20. [
PubMed: 11236835]
Ranta K, Kaltiala-Heino R, Rantanen P, Marttunen M. Social phobia in Finnish general adolescent population: prevalence, comorbidity, individual and family correlates, and service use.
Depression and Anxiety. 2009;26:528–36. [
PubMed: 19170089]
Rapee RM. Overcoming Shyness and Social Phobia: A Step by Step Guide. Lanham, MD: Jason Aronson; 1998.
Rapee RM, Abbott MJ, Lyneham HJ. Bibliotherapy for children with anxiety disorders using written materials for parents: a randomized controlled trial.
Journal of Consulting and Clinical Psychology. 2006;74:436–44. [
PubMed: 16822101]
Rapee RM, Abbott MJ, Baillie AJ, Gaston JE. Treatment of social phobia through pure self-help and therapist-augmented self-help.
British Journal of Psychiatry. 2007;191:246–52. [
PubMed: 17766766]
Rapee RM, Gaston JE, Abbott MJ. Testing the efficacy of theoretically derived improvements in the treatment of social phobia.
Journal of Consulting and Clinical Psychology. 2009;77:317–27. [
PubMed: 19309190]
Ravindran LN, Kim DS, Letamendi AM, Stein MB. A randomized controlled trial of atomoxetine in generalized social anxiety disorder.
Journal of Clinical Psychopharmacology. 2009;29:561–64. [
PubMed: 19910721]
Reich J, Goldenberg I, Goisman R, Vasile R, Keller M. A prospective, follow-along study of the course of social phobia: II. Testing for basic predictors of course.
The Journal of Nervous and Mental Disease. 1994;182:297–301. [
PubMed: 10678312]
Reich J, Goldenberg I, Vasile R, Goisman R, Keller M. A prospective follow-along study of the course of social phobia.
Psychiatry Research. 1994;54:249–58. [
PubMed: 7792329]
Renner KA. Overall effectiveness and cognitive mediators of a brief intensive treatment for social anxiety. Dissertation Abstracts International: Section B: The Sciences and Engineering. 2008:69.
Revicki DA, Wood M. Patient-assigned health state utilities for depression-related outcomes: differences by depression severity and antidepressant medications.
Journal of Affective Disorders. 1998;48:25–36. [
PubMed: 9495599]
Rickels K, Mangano R, Khan A. A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder.
Journal of Clinical Psychopharmacology. 2004;24:488–96. [
PubMed: 15349004]
Roberson-Nay R, Strong DR, Nay WT, Beidel DC, Turner SM, Roberson-Nay R, et al. Development of an abbreviated Social Phobia and Anxiety Inventory (SPAI) using item response theory: the SPAI-23.
Psychological Assessment. 2007;19:133–45. [
PubMed: 17371128]
Robillard G, Bouchard S, Dumoulin S, Guitard T, Klinger E. Using virtual humans to alleviate social anxiety: preliminary report from a comparative outcome study.
Studies in Health Technology and Informatics. 2010;154:2010. [
PubMed: 20543270]
Rodebaugh TL, Chambless DL, Terrill DR, Floyd M, Uhde T. Convergent, discriminant, and criterion-related validity of the Social Phobia and Anxiety Inventory.
Depression and Anxiety. 2000;11:10–14. [
PubMed: 10723630]
Rosenbaum JF, Fava M, Hoog SL, Ascroft RC, Krebs WB. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial.
Biological Psychiatry. 1998;44:77–87. [
PubMed: 9646889]
Ross J. Social phobia: the Anxiety Disorders Associated of America helps raise the veil of ignorance.
Journal of Clinical Psychiatry. 1991;52(Suppl.):43–7. [
PubMed: 1757456]
Rytwinski NK, Fresco DM, Heimberg RG, Coles ME, Liebowitz MR, Cissell S, et al. Screening for social anxiety disorder with the self-report version of the Liebowitz Social Anxiety Scale.
Depression and Anxiety. 2009;26:34–38. [
PubMed: 18781659]
Saarni SI, Suvisaari J, Sintonen H, Pirkola S, Koskinen S, Aromaa A, et al. Impact of psychiatric disorders on health-related quality of life: general population survey.
The British Journal of Psychiatry. 2007;190:326–32. [
PubMed: 17401039]
Salaberria K, Echeburua E. Long-term outcome of cognitive therapy's contribution to self-exposure in vivo to the treatment of generalized social phobia.
Behavior Modification. 1998;22:262–84. [
PubMed: 9670800]
Sanderson WC, Wetzler S, Beck AT, Betz F. Prevalence of personality disorders among patients with anxiety disorders.
Psychiatry Research. 1994;51:167–74. [
PubMed: 8022951]
Sattler JM. Assessment of Children: Cognitive Applications. 4th ed. San Diego: Jerome M. Sattler Publisher Inc; 2001.
Scharfstein L, Beidel D, Finnell LR, Distler A, Carter N. Do pharmacological and behavioral interventions differentially affect treatment outcome for children with social phobia?
Behavior Modification. 2011;35:451–67. [
PubMed: 21586501]
Schmidt NB, Richey JA, Buckner JD, Timpano KR. Attention training for generalized social anxiety disorder.
Journal of Abnormal Psychology. 2009;118:5–14. [
PubMed: 19222309]
Schneider AJ, Mataix-Cols D, Marks IM, Bachofen M, Schneider AJ, Mataix-Cols D, et al. Internet-guided self-help with or without exposure therapy for phobic and panic disorders.
Psychotherapy and Psychosomatics. 2005;74:154–64. [
PubMed: 15832066]
Schneier FR, Goetz D, Campeas R, Fallon B, Marshall R, Liebowitz MR. Placebo-controlled trial of moclobemide in social phobia.
British Journal of Psychiatry. 1998;172:70–77. [
PubMed: 9534836]
Schutters SI, Van Megen HJ, Van Veen JF, Denys DA, Westenberg HG. Mirtazapine in generalized social anxiety disorder: a randomized, double-blind, placebo-controlled study.
International Clinical Psychopharmacology. 2010;25:302–04. [
PubMed: 20715300]
Schwartz RH, Freedy AS, Sheridan MJ, Schwartz RH, Freedy AS, Sheridan MJ. Selective mutism: are primary care physicians missing the silence?
Clinical Pediatrics. 2006;45:43–48. [
PubMed: 16429215]
Seedat S, Stein MB. Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorder.
Journal of Clinical Psychiatry. 2004;65:244–48. [
PubMed: 15003080]
Servant D, Montgomery SA, Francois C, Despiegel N. Cost-effectiveness of escitalopram versus placebo in relapse prevention in patients with social anxiety disorder. Value in Health. 2003;6:351–51.
Shaw P. A comparison of three behaviour therapies in the treatment of social phobia.
British Journal of Psychiatry. 1979;134:620–23. [
PubMed: 38878]
Silverman WK, Albano AM. Anxiety Disorders Interview Schedule (ADIS-IV) Child and Parent Interview Schedules. Oxford: Oxford University Press; 1996.
Simon NM, Otto MW, Wisniewski SR, Fossey M, Sagduyu K, Frank E, et al. Anxiety disorder comorbidity in bipolar disorder patients: data from the first 500 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD).
The American Journal of Psychiatry. 2004;161:2222–9. [
PubMed: 15569893]
Simon NM, Worthington JJ, Moshier SJ, Marks EH, Hoge EA, Brandes M, et al. Duloxetine for the treatment of generalized social anxiety disorder: a preliminary randomized trial of increased dose to optimize response.
CNS Spectrums. 2010;15:367–73. [
PubMed: 20625362]
Simonoff E, Pickles A, Charman T, Chandler S, Loucas T, Baird G. Psychiatric disorders in children with autism spectrum disorders: prevalence, comorbidity, and associated factors in a population-derived sample.
Journal of the American Academy of Child and Adolescent Psychiatry. 2008;47:921–9. [
PubMed: 18645422]
Simpson HB, Fallon BA. Obsessive-compulsive disorder: an overview.
Journal of Psychiatric Practice. 2000;6:3–17. [
PubMed: 15990471]
Singleton N, Bumpstead R, O'Brien M, Lee A, Meltzer H. Psychiatric morbidity among adults living in private households. London: The Stationery Office; 2001.
Sir A, D'Souza RF, Uguz S, George T, Vahip S, Hopwood M, et al. Randomized trial of sertraline versus venlafaxine XR in major depression: efficacy and discontinuation symptoms.
Journal of Clinical Psychiatry. 2005;66:1312–20. [
PubMed: 16259546]
Smith KL, Kirkby KC, Montgomery IM, Daniels BA. Computer-delivered modeling of exposure for spider phobia: relevant versus irrelevant exposure.
Journal of Anxiety Disorders. 1997;11:489–97. [
PubMed: 9407268]
Smits JA, Powers MB, Buxkamper R, Telch MJ. The efficacy of videotape feedback for enhancing the effects of exposure-based treatment for social anxiety disorder: a controlled investigation.
Behaviour Research and Therapy. 2006;44:1773–85. [
PubMed: 16488388]
Sonntag H, Wittchen HU, Hofler M, Kessler RC, Stein MB. Are social fears and DSM-IV social anxiety disorder associated with smoking and nicotine dependence in adolescents and young adults?
European Psychiatry. 2000;15:67–74. [
PubMed: 10713804]
Spence SH, Donovan C, Brechman-Toussaint M. The treatment of childhood social phobia: the effectiveness of a social skills training-based, cognitive-behavioural intervention, with and without parental involvement.
Journal of Child Psychology and Psychiatry and Allied Disciplines. 2000;41:713–26. [
PubMed: 11039684]
Spence SH, Barrett PM, Turner CM. Psychometric properties of the Spence Children's Anxiety Scale with young adolescents.
Journal of Anxiety Disorders. 2003;17:605–25. [
PubMed: 14624814]
Spence SH, Donovan CL, March S, Gamble A, Anderson RE, Prosser S, et al. A randomized controlled trial of online versus clinic-based CBT for adolescent anxiety.
Journal of Consulting and Clinical Psychology. 2011;79:629–42. [
PubMed: 21744945]
Spiegelhalter DJ. Bayesian methods for cluster randomized trials with continuous responses.
Statistics in Medicine. 2001;20:435–52. [
PubMed: 11180312]
Stangier U, Heidenreich T, Peitz M, Lauterbach W, Clark DM. Cognitive therapy for social phobia: individual versus group treatment.
Behaviour Research and Therapy. 2003;41:991–1007. [
PubMed: 12914803]
Stangier U, Schramm E, Heidenreich T, Berger M, Clark DM. Cognitive therapy vs interpersonal psychotherapy in social anxiety disorder: A randomized controlled trial.
Archives of General Psychiatry. 2011;68:692–700. [
PubMed: 21727253]
Stein DJ, Berk M, Els C, Emsley RA, Gittelson L, Wilson D, et al. A double-blind placebo-controlled trial of paroxetine in the management of social phobia (social anxiety disorder) in South Africa.
South African Medical Journal. 1999;89:402–06. [
PubMed: 10341825]
Stein D, Ipser J, van Balkom A. Pharmacotherapy for social anxiety disorder. Cochrane Database of Systematic Reviews. 2000. CD001206.
Stein DJ, Stein MB, Goodwin W, Kumar R, Hunter B. The selective serotonin reuptake inhibitor paroxetine is effective in more generalized and in less generalized social anxiety disorder.
Psychopharmacology. 2001;158:267–72. [
PubMed: 11713616]
Stein DJ, Cameron A, Amrein R, Montgomery SA. Moclobemide is effective and well tolerated in the long-term pharmacotherapy of social anxiety disorder with or without comorbid anxiety disorder.
International Clinical Psychopharmacology. 2002;17:161–70. [
PubMed: 12131599]
Stein DJ, Versiani M, Hair T, Kumar R. Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24–week study.
Archives of General Psychiatry. 2002;59:1111–18. [
PubMed: 12470127]
Stein DJ, Westenberg HG, Yang H, Li D, Barbato LM. Fluvoxamine CR in the long-term treatment of social anxiety disorder: the 12- to 24-week extension phase of a multicentre, randomized, placebo-controlled trial.
International Journal of Neuropsychopharmacology. 2003;6:317–23. [
PubMed: 14604447]
Stein DJ, Andersen EW, Lader M. Escitalopram versus paroxetine for social anxiety disorder: an analysis of efficacy for different symptom dimensions.
European Neuropsychopharmacology. 2006;16:33–38. [
PubMed: 16014329]
Stein MB, Chartier MJ, Hazen AL, Kozak MV, Tancer ME, Lander S, et al. A direct-interview family study of generalized social phobia.
The American Journal of Psychiatry. 1998;155:90–7. [
PubMed: 9433344]
Stein MB, Liebowitz MR, Lydiard RB, Pitts CD, Bushnell W, Gergel I. Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial.
Journal of the American Medical Association. 1998;280:708–13. [
PubMed: 9728642]
Stein MB, Fyer AJ, Davidson JR, Pollack MH, Wiita B. Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study.
American Journal of Psychiatry. 1999;156:756–60. [
PubMed: 10327910]
Stein MB, McQuaid JR, Laffaye C, McCahill ME. Social phobia in the primary care medical setting.
The Journal of Family Practice. 1999;48:514–9. [
PubMed: 10428248]
Stein MB, Pollack MH, Bystritsky A, Kelsey JE, Mangano RM. Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial.
Psychopharmacology. 2005;177:280–88. [
PubMed: 15258718]
Stinson FS, Dawson DA, Patricia Chou S, Smith S, Goldstein RB, June Ruan W, et al. The epidemiology of DSM-IV specific phobia in the USA: results from the National Epidemiologic Survey on Alcohol and Related Conditions.
Psychological Medicine. 2007;37:1047–59. [
PubMed: 17335637]
Stone M, Laughren T, Jones ML, Levenson M, Holland PC, Hughes A, et al. Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration.
BMJ. 2009;339:b2880. [
PMC free article: PMC2725270] [
PubMed: 19671933]
Stravynski A, Arbel N, Bounader J, Gaudette G, Lachance L, Borgeat F, et al. Social phobia treated as a problem in social functioning: a controlled comparison of two behavioural group approaches.
Acta Psychiatrica Scandinavica. 2000;102:188–98. [
PubMed: 11008854]
Sutherland SM, Tupler LA, Colket JT, Davidson JR. A 2–year follow-up of social phobia. Status after a brief medication trial.
Journal of Nervous and Mental Disease. 1996;184:731–38. [
PubMed: 8994456]
Swenson JR, Doucette S, Fergusson D. Adverse cardiovascular events in antidepressant trials involving high-risk patients: a systematic review of randomized trials.
Canadian Journal of Psychiatry Revue Canadienne de Psychiatrie. 2006;51:923–9. [
PubMed: 17249635]
Taylor D. Antidepressant drugs and cardiovascular pathology: a clinical overview of effectiveness and safety.
Acta Psychiatrica Scandinavica. 2008;118:434–42. [
PubMed: 18785947]
Taylor D, Stewart S, Connolly A. Antidepressant withdrawal symptoms: telephone calls to a national medication helpline.
Journal of Affective Disorders. 2006;95:129–33. [
PubMed: 16797080]
Thirlwall K, Cooper P, Karalus J, Voysey M, Willetts L, Creswell C. The treatment of child anxiety disorders via guided CBT self-help: randomised controlled trial. 2012 Under review.
Tillfors M. Why do some individuals develop social phobia? A review with emphasis on the neurobiological influences.
Nordic Journal of Psychiatry. 2004;58:267–76. [
PubMed: 15370775]
Tillfors M, Carlbring P, Furmark T, Lewenhaupt S, Spak M, Eriksson A, et al. Treating university students with social phobia and public speaking fears: internet delivered self-help with or without live group exposure sessions.
Depression and Anxiety. 2008;25:708–17. [
PubMed: 18729147]
Tillfors M, Andersson G, Ekselius L, Furmark T, Lewenhaupt S, Karlsson A, et al. A randomized trial of internet-delivered treatment for social anxiety disorder in high school students.
Cognitive Behaviour Therapy. 2011;40:147–57. [
PubMed: 25155815]
Tint A, Haddad PM, Anderson IM. The effect of rate of antidepressant tapering on the incidence of discontinuation symptoms: a randomised study.
Journal of Psychopharmacology. 2008;22:330–2. [
PubMed: 18515448]
Titov N, Andrews G, Choi I, Schwencke G, Mahoney A. Shyness 3: randomized controlled trial of guided versus unguided internet-based CBT for social phobia.
Australian and New Zealand Journal of Psychiatry. 2008;42:1030–40. [
PubMed: 19016091]
Titov N, Andrews G, Schwencke G. Shyness 2: treating social phobia online: replication and extension.
Australian and New Zealand Journal of Psychiatry. 2008;42:595–605. [
PubMed: 18612863]
Titov N, Andrews G, Schwencke G, Drobny J, Einstein D. Shyness 1: distance treatment of social phobia over the internet.
Australian and New Zealand Journal of Psychiatry. 2008;42:585–94. [
PubMed: 18612862]
Titov N, Andrews G, Choi I, Schwencke G, Johnston L. Randomized controlled trial of web-based treatment of social phobia without clinician guidance. Australian and New Zealand Journal of Psychiatry. 2009;43:913–19.
Titov N, Andrews G, Johnston L, Schwencke G, Choi I. Shyness programme: longer term benefits, cost-effectiveness, and acceptability. (Provisional abstract).
Australian and New Zealand Journal of Psychiatry. 2009;43:36–44. [
PubMed: 19085526]
Titov N, Andrews G, Schwencke G, Solley K, Johnston L, Robinson E. An RCT comparing effect of two types of support on severity of symptoms for people completing internet-based cognitive behaviour therapy for social phobia. Australian and New Zealand Journal of Psychiatry. 2009;43:920–26.
Titov N, Gibson M, Andrews G, McEvoy P. Internet treatment for social phobia reduces comorbidity.
Australian and New Zealand Journal of Psychiatry. 2009;43:754–9. [
PubMed: 19629797]
Titov N, Andrews G, Schwencke G, Robinson E, Peters L, Spence J. Randomized controlled trial of internet cognitive behavioural treatment for social phobia with and without motivational enhancement strategies.
Australian and New Zealand Journal of Psychiatry. 2010;44:938–45. [
PubMed: 20932208]
Tortella-Feliu M, Botella C, Llabrés J, Bretón-López JM, del Amo AR, Baños RM, et al. Virtual reality versus computer-aided exposure treatments for fear of flying.
Behavior Modification. 2011;35:3–30. [
PubMed: 21177516]
Turk CL, Heimberg RG, Orsillo SM, Holt CS, Gitow A, Street LL, et al. An investigation of gender differences in social phobia.
Journal of Anxiety Disorders. 1998;12:209–23. [
PubMed: 9653680]
Turner SM, Beidel DC, Dancu CV. Social Phobia and Anxiety Inventory: Manual. Toronto: Multi-Health Systems Inc.; 1996.
Vaishnavi S, Alamy S, Zhang W, Connor KM, Davidson JR. Quetiapine as monotherapy for social anxiety disorder: a placebo-controlled study.
Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2007;31:1464–69. [
PubMed: 17698275]
Van Ameringen M, Swinson R, Walker JR, Lane RM. A placebo-controlled study of sertraline in generalized social phobia. Journal of the European College of Neuropsychopharmacology. 1999;9:S235.
Van Ameringen MA, Lane RM, Walker JR, Bowen RC, Chokka PR, Goldner EM, et al. Sertraline treatment of generalized social phobia: a 20–week, double-blind, placebo-controlled study.
American Journal of Psychiatry. 2001;158:275–81. [
PubMed: 11156811]
Van Ameringen M, Mancini C, Farvolden P. The impact of anxiety disorders on educational achievement.
Journal of Anxiety Disorders. 2003;17:561–71. [
PubMed: 12941366]
Van Ameringen M, Oakman J, Mancini C, Pipe B, Chung H. Predictors of response in generalized social phobia: effect of age of onset.
Journal of Clinical Psychopharmacology. 2004;24:42–48. [
PubMed: 14709946]
Van Gastel WF. Screening capacity of the Multidimensional Anxiety Scale for Children (MASC) for DSM-IV anxiety disorders.
Depression and Anxiety. 2008;25:1046–52. [
PubMed: 18833579]
Van Vliet IM, den Boer JA, Westenberg HG. Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor.
European Neuropsychopharmacology. 1992;2:21–29. [
PubMed: 1638170]
Van Vliet IM, Boer JA, Westenberg HGM. Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine.
Psychopharmacology. 1994;115:128–34. [
PubMed: 7862884]
Versiani M, Nardi AE, Mundim FD, Alves AB, Liebowitz MR, Amrein R. Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine.
British Journal of Psychiatry. 1992;161:353–60. [
PubMed: 1393304]
Viana AG, Beidel DC, Rabian B. Selective mutism: a review and integration of the last 15 years.
Clinical Psychology Review. 2009;29:57–67. [
PubMed: 18986742]
Walker JRV. Prevention of relapse in generalized social phobia: results of a 24-week study in responders to 20 weeks of sertraline treatment.
Journal of Clinical Psychopharmacology. 2000;20:636–44. [
PubMed: 11106135]
Walker JR, Ameringen MAV, Swinson RP, Lane RM, editors. A 24-week prevention of relapse of generalized social phobia study in responders to 20 weeks of sertraline treatment; 155th Annual Meeting of the American Psychiatric Association; Philadelphia, PA. 18–23 May 2002.
Wang PS, Lane M, Olfson M, Pincus HA, Wells KB, Kessler RC. Twelve-month use of mental health services in the United States: results from the National Comorbidity Survey Replication.
Archives of General Psychiatry. 2005;62:629–40. [
PubMed: 15939840]
Watson D, Friend R. Measurement of social-evaluative anxiety.
Journal of Consulting and Clinical Psychology. 1969;33:448–57. [
PubMed: 5810590]
Weeks JW, Spokas ME, Heimberg RG. Psychometric evaluation of the mini-social phobia inventory (Mini-SPIN) in a treatment-seeking sample.
Depression and Anxiety. 2007;24:382–91. [
PubMed: 17099878]
Weinrieb RM, Auriacombe M, Lynch KG, Chang KM, Lewis JD. A critical review of selective serotonin reuptake inhibitor-associated bleeding: balancing the risk of treating hepatitis C-infected patients.
Journal of Clinical Psychiatry. 2003;64:1502–10. [
PubMed: 14728113]
Werneke U, Northey S, Bhugra D. Antidepressants and sexual dysfunction.
Acta Psychiatrica Scandinavica. 2006;114:384–97. [
PubMed: 17087787]
Wernicke J, Lledo A, Raskin J, Kajdasz DK, Wang F. An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies.
Drug Safety. 2007;30:437–55. [
PubMed: 17472422]
Westenberg HG, Stein DJ, Yang H, Li D, Barbato LM. A double-blind placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder.
Journal of Clinical Psychopharmacology. 2004;24:49–55. [
PubMed: 14709947]
Whisman MA, Sheldon CT, Goering P. Psychiatric disorders and dissatisfaction with social relationships: does type of relationship matter?
Journal of Abnormal Psychology. 2000;109:803–8. [
PubMed: 11196008]
Wiltink J, Ruckes C, Haselbacher A, Canterino M, Leichsenring F, Joraschky P, et al. Transfer of manualized short term psychodynamic psychotherapy (STPP) for social phobia into clinical practice: study protocol for a cluster-randomised controlled trial.
Trials. 2011;12:142. [
PMC free article: PMC3123564] [
PubMed: 21651760]
Wittchen HU, Fehm L. Epidemiology and natural course of social fears and social phobia.
Acta Psychiatrica Scandinavica Supplementum. 2003:4–18. [
PubMed: 12950432]
Wittchen HU, Jacobi F. Size and burden of mental disorders in Europe: a critical review and appraisal of 27 studies.
European Neuropsychopharmacology. 2005;15:357–76. [
PubMed: 15961293]
Wittchen HU, Fuetsch M, Sonntag H, Muller N, Liebowitz M. Disability and quality of life in pure and comorbid social phobia: findings from a controlled study.
European Psychiatry. 1999;14:118–31. [
PubMed: 10572336]
Wittchen HU, Stein MB, Kessler RC. Social fears and social phobia in a community sample of adolescents and young adults: prevalence, risk factors and co-morbidity.
Psychological Medicine. 1999;29:309–23. [
PubMed: 10218923]
Wittchen HU, Lecrubier Y, Beesdo K, Nocon A. Relationships among anxiety disorders: patterns and implications. In: Nutt DJ, Ballenger JC, editors. Anxiety Disorders. Malden, MA: Blackwell; 2007. pp. 23–37.
Wolpe J. Psychotherapy by reciprocal inhibition.
Conditional Reflex. 1968;3:234–40. [
PubMed: 5712667]
Wong DFK, Sun SYK. A preliminary study of the efficacy of group cognitive-behavioural therapy for people with social anxiety in Hong Kong. Hong Kong Journal of Psychiatry. 2007;16:50–56.
World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Description and Diagnostic Guidelines. Geneva: World Health Organization; 1992.
Wren FJ, Berg EA, Heiden LA, Kinnamon CJ, Ohlson LA, Bridge JA, et al. Childhood anxiety in a diverse primary care population: parent-child reports, ethnicity and SCARED factor structure.
Journal of the American Academy of Child and Adolescent Psychiatry. 2007;46:332–40. [
PubMed: 17314719]
Young BJ, Beidel DC, Turner SM, Ammerman RT, McGraw K, Coaston SC. Pretreatment attrition and childhood social phobia: parental concerns about medication.
Journal of Anxiety Disorders. 2006;20:1133–47. [
PubMed: 16635559]
Yuan Y, Tsoi K, Hunt RH. Selective serotonin reuptake inhibitors and risk of upper GI bleeding: confusion or confounding?
The American Journal of Medicine. 2006;119:719–27. [
PubMed: 16945603]
Zhang W, Connor KM, Davidson JR. Levetiracetam in social phobia: a placebo controlled pilot study.
Journal of Psychopharmacology. 2005;19:551–53. [
PubMed: 16166192]
